Document:

RFP-2014.9.30-EX10.2

EXHIBIT 10.2

RESOLUTE FOREST PRODUCTS EQUITY INCENTIVE PLAN 
RESTRICTED STOCK UNIT AGREEMENT
THIS RESTRICTED STOCK UNIT AGREEMENT, dated as of MONTH, DAY, YEAR (the “Date of Grant”) is made by and between Resolute Forest Products Inc., a Delaware corporation (the “Company”), and «FIRST» «LAST» (“Participant”).
WHEREAS, the Company has adopted the Resolute Forest Products Equity Incentive Plan (the “Plan”), pursuant to which restricted stock units may be granted in respect of shares of the Company’s common stock, par value $0.001 per share (“Stock”); and
WHEREAS, the Human Resources and Compensation and Nominating and Governance Committee of the Company (the “Committee”) has determined that it is in the best interests of the Company and its stockholders to grant the restricted stock unit award provided for herein to Participant subject to the terms set forth herein.
NOW, THEREFORE, for and in consideration of the premises and the covenants of the parties contained in this Agreement, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto, for themselves, their successors and assigns, hereby agree as follows:
1.Grant of Restricted Stock Unit.
(a)    Grant.  The Company hereby grants to Participant «RSUs» restricted stock units (the “RSUs”), on the terms and conditions set forth in this Agreement and as otherwise provided in the Plan (the "Initial Grant").  Each RSU represents the right to receive one share of Stock as of the Settlement Date (defined in Section 2(b)), to the extent the Participant is vested in such RSUs as of the Settlement Date, subject to the terms of this Agreement and the Plan.
(b)    Incorporation by Reference, Etc.  The provisions of the Plan are hereby incorporated herein by reference.  Except as otherwise expressly set forth herein, this Agreement shall be construed in accordance with the provisions of the Plan and any interpretations, amendments, rules and regulations promulgated by the Committee from time to time pursuant to the Plan. Any capitalized terms not otherwise defined in this Agreement shall have the definitions set forth in the Plan.  The Committee shall have final authority to interpret and construe the Plan and this Agreement and to make any and all determinations under them, and its decision shall be binding and conclusive upon Participant and his legal representative in respect of any questions arising under the Plan or this Agreement.
(c)    Acceptance of Agreement.  Unless Participant notifies the Company in writing within 14 days after the Date of Grant that Participant does not wish to accept this Agreement, Participant will be deemed to have accepted this Agreement and will be bound by the terms of the Agreement and the Plan.  Any such notice may be given to the Director, Corporate Compensation at the Company’s principal executive office.

2.    Terms and Conditions.
(a)    Vesting.  Subject to continued employment with the Company or any Affiliate or Subsidiary or in the case of terminations of employment due to Retirement as provided in Section 3(a), twenty five percent (25%) of the RSUs (rounded to the nearest whole restricted stock unit) shall vest on each of the first four anniversaries of the Date of Grant (each such date, a “Vesting Date”).
(b)    Settlement.   The obligation to make payments and distributions with respect to RSUs shall only be satisfied through the issuance of one share of Stock for each vested RSU (the “settlement”) and the settlement of the RSUs may be subject to such conditions, restrictions and contingencies as the Committee shall determine.  The Company undertakes and agrees not to exercise its right under the Plan to settle the RSUs in any other means other than Stock.  RSUs shall be settled as soon as practicable after the earliest of (i) the applicable Vesting Date, (ii) an involuntary termination of employment by the Company or any Affiliate or Subsidiary of a Participant who will not attain age 55 at any time before the fourth anniversary of the Date of Grant, (iii) the Vesting Date that immediately follows (A) an involuntary termination of employment by the Company or any Affiliate or Subsidiary of a Participant who otherwise meets the criteria for Retirement at any time before the fourth anniversary of the Date of Grant, but for the receipt of severance, (B) voluntary termination by the Participant on or after age 55 that does not constitute a Retirement, or (C) Retirement (as defined in Section 3(a)) within six months after the Date of Grant, (iv) death, or (v) termination of employment by reason of Disability.  For payment time or events described in clauses (i), (ii), (iv) and (v), settlement shall in no event be later than March 15 of the year following the year of such payment time or event, as applicable.  For purposes of this Agreement, each date on which RSUs are settled pursuant to the preceding sentence shall be a “Settlement Date.”  For purposes of this Agreement and to the extent applicable to the Participant, the term “termination of employment” shall be interpreted to comply with Section 409A of the Internal Revenue Code (“Section 409A”).  To the extent payments are made during the periods permitted under Section 409A (including any applicable periods before or after the specified payment dates set forth in this Section 2(b)), the Company shall be deemed to have satisfied its obligations under the Plan and shall be deemed not to be in breach of its payments obligations hereunder.
(c)    Dividend Equivalents and Voting Rights.  Participant will from time to time be credited with additional RSUs (including a fractional RSU), the number of which will be determined by dividing: 
(i)    The product obtained by multiplying the amount of each dividend (including extraordinary dividend if so determined by the Company) declared and paid by the Company on the Stock on a per share basis during the Vesting Period by the number of RSUs recorded in Participant's account on the record date for payment of any such dividend, by
(ii)    The Fair Market Value of one (1) share of Stock on the dividend payment date for such dividend.

2

Subject to continued employment with the Company or any Affiliate or Subsidiary or as otherwise provided in Section 3, the additional RSUs shall vest and be settled at the same time and in the same proportion as the Initial Grant.  No additional RSUs shall be accrued for the benefit of Participant with respect to record dates occurring before, or with respect to record dates occurring on or after the date, if any, on which Participant has forfeited the RSUs. Participant shall not be a shareholder of record with respect to the RSUs and shall have no voting rights with respect to the RSUs.
3.    Termination of Employment with the Company.
(a)    Retirement.  If the Participant’s employment with the Company, Affiliates and Subsidiaries terminates as a result of “Retirement” at any time on or after six months from the Date of Grant has elapsed, then Section 2(a) shall continue to apply to the Participant and the Participant shall receive settlement of RSUs following each Vesting Date, unless Section 3(c) applies.  For purposes of the Agreement, “Retirement” means the Participant terminates employment with the Company, all Affiliates and Subsidiaries under circumstances that do not entitle the Participant to severance either pursuant to an agreement or policy, plan or program and such termination occurs on or after: (i) attaining age 58, (ii) completing at least two years of service, and (iii) having a combined age and years of service (counting partial years) equal to at least 62.5 points.  
(b)    Involuntary Termination and Certain Voluntary Terminations. The Participant shall become vested in a prorated number of RSUs in the following circumstances: (1) the Participant’s employment with the Company or any Affiliate or Subsidiary terminates as a result of Retirement within six months after the Date of Grant, (2) the Participant voluntarily terminates his employment with the Company, Affiliates and Subsidiaries on or after age 55 and the termination does not constitute a Retirement, or (3) the Participant is involuntarily terminated by the Company or any Affiliate or Subsidiary without Cause (whether or not the Participant is eligible for Retirement, regardless of his age at termination and other than due to Disability or death).  For purposes of the preceding, the prorated portion of the RSUs that is vested as of the Participant’s retirement date or date of termination, as applicable, including the portion of the RSUs then already vested, shall be the total number of granted and credited RSUs multiplied by a fraction, the numerator of which shall be the number of full months elapsed from the Date of Grant through the Participant’s retirement date or last day worked (in the case of termination) and the denominator of which shall be 48. 
(c)    Death. If the Participant’s employment with the Company or any Affiliate or Subsidiary terminates due to the Participant’s death, then, in addition to the RSUs vested as of the date of death under Section 2(a), the RSUs scheduled to vest on the next scheduled Vesting Date shall also vest on the date of death. 
(d)    Disability. If the Participant becomes eligible for long-term disability benefits under a  plan sponsored by the Company, an Affiliate or a Subsidiary, then, in addition to the RSUs then vested, the RSUs scheduled to vest on the next scheduled Vesting Date shall also vest on the first date of the long-term disability period.  For the avoidance of doubt, RSUs shall continue to vest during any short-term disability period. 

3

(e)    Other Termination. If the Participant’s employment with the Company, all Affiliates and Subsidiaries terminates for Cause or resignation (before attainment of age 55 and before Retirement eligibility) then all outstanding RSUs, whether vested but unsettled or unvested, shall immediately terminate.
Notwithstanding anything contained to the contrary in this Section 3, in no event shall any RSUs be settled before the applicable Vesting Date except if otherwise determined by the Company.
4.    Compliance with Legal Requirements.  The granting and settlement of the RSUs, and any other obligations of the Company under this Agreement, shall be subject to all applicable federal, provincial, state, local and foreign laws, rules and regulations and to such approvals by any regulatory or governmental agency as may be required.  
(a)    Transferability.  Unless otherwise provided by the Committee in writing, the RSUs shall not be transferable by Participant other than by will or the laws of descent and distribution.
(b)    No Rights as Stockholder.  The Participant shall not be deemed for any purpose to be the owner of any shares of Stock subject to RSUs.
(c)    Tax Withholding.  All distributions under the Plan are subject to withholding of all applicable federal, state, provincial, local and foreign income taxes and social contributions (the “Withholding Obligation”). The Company may satisfy such Withholding Obligation by any means whatsoever, including withholding cash from any other payment or amounts due to the Participant. Unless otherwise determined by the Committee, the Company will satisfy its Withholding Obligation by issuing, upon the settlement of the RSUs, a net number of Stocks to the Participant equal to the number of Stocks that the Participant would otherwise be entitled to receive on the Settlement Date minus such number of Stocks with a value determined on that date equal to any amount required to satisfy the Withholding Obligation.
5.    Miscellaneous.
(a)    Waiver.  Any right of the Company contained in this Agreement may be waived in writing by the Committee.  No waiver of any right hereunder by any party shall operate as a waiver of any other right, or as a waiver of the same right with respect to any subsequent occasion for its exercise, or as a waiver of any right to damages.  No waiver by any party of any breach of this Agreement shall be held to constitute a waiver of any other breach or a waiver of the continuation of the same breach.
(b)    Notices.  Any written notices provided for in this Agreement or the Plan shall be in writing and shall be deemed sufficiently given if either hand delivered or if sent by fax or overnight courier, or by postage paid first class mail.  Notices sent by mail shall be deemed received three business days after mailing but in no event later than the date of actual receipt.  Notices shall be directed, if to the Participant, at the Participant’s address indicated by the Company’s records, or if to the Company, to the attention of the Director, Corporate Compensation at the Company’s principal executive office.  

4

(c)    Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, and each other provision of this Agreement shall be severable and enforceable to the extent permitted by law.
(d)    No Rights to Employment.  Nothing contained in this Agreement shall be construed as giving Participant any right to be retained, in any position, as an employee, consultant or director of the Company or its Affiliates or shall interfere with or restrict in any way the right of the Company or its Affiliates, which are hereby expressly reserved, to remove, terminate or discharge Participant at any time for any reason whatsoever.
(e)    Beneficiary.  The Participant other than a Participant residing in the Province of Québec, may file with the Committee a written designation of a beneficiary on such form as may be prescribed by the Committee and may, from time to time, amend or revoke such designation.  Any notice should be made to the attention of the Corporate Secretary of the Company at the Company’s principal executive office.  If no designated beneficiary survives the Participant, the Participant’s estate shall be deemed to be Participant’s beneficiary.
(f)    Québec Participant.  The Participant residing in the Province of Québec may only designate a beneficiary by will. Upon the death of the Participant residing in the Province of Québec, the Company shall settle the RSUs pursuant to Section 2(b) of this Agreement to the liquidator, administrator or executor of the estate of the Participant.
(g)    Successors.  The terms of this Agreement shall be binding upon and inure to the benefit of the Company and its successors and assigns, and of the Participant and the beneficiaries, executors, administrators, heirs and successors of the Participant.
(h)    Entire Agreement.  This Agreement and the Plan contain the entire agreement and understanding of the parties hereto with respect to the subject matter contained herein and supersede all prior communications, representations and negotiations in respect thereto.  No change, modification or waiver of any provision of this Agreement shall be valid unless the same be in writing and signed by the parties hereto, except for any changes permitted without consent under Section 9 of the Plan.
(i)    Governing Law.  This Agreement shall be construed and interpreted in accordance with the laws of the State of Delaware without regard to principles of conflicts of law thereof, or principles of conflicts of laws of any other jurisdiction which could cause the application of the laws of any jurisdiction other than the State of Delaware.
(j)    Headings.  The headings of the Sections hereof are provided for convenience only and are not to serve as a basis for interpretation or construction, and shall not constitute a part, of this Agreement.

5

IN WITNESS WHEREOF, the Company has executed this Agreement as of the day first written above.

RESOLUTE FOREST PRODUCTS INC. 

By:                                                              
Name:
Title:     

6Orgenesis Inc.: Exhibit 10.1 - Filed by newsfilecorp.com

Execution version 

SHARE EXCHANGE AGREEMENT 

THIS AGREEMENT is made effective as of the 3rd day of November,
2014 

AMONG: 

	
      ORGENESIS INC. a Nevada corporation with an office
      at 21 Sparrow Circle, White Plains NY 10605 

	  
	(“Pubco”) 

AND: 

	
      MASTHERCELL SA, a company incorporated and
      existing under the laws of Belgium, having its registered office at 6041
      Gosselies, rue Auguste Piccard 48, Belgium, registered with the Belgian
      RPM under number 0840.843.708 (“MasTHerCell”); and 

	  
	
      CELL THERAPY HOLDING SA, a company incorporated
      and existing under the laws of Belgium, having its registered office at
      6041 Gosselies, rue Auguste Piccard 48, Belgium, registered with the
      Belgian RPM under number 0840.625.061 (“CTH”) 

	  
	(together called “Priveco”)

AND: 

THE UNDERSIGNED SHAREHOLDERS OF PRIVECO AS LISTED ON
SCHEDULE 1 ATTACHED HERETO 

(together with the Bondholders in case of conversion, the
“Selling Shareholders”) 

WHEREAS: 

	A. 	
      The Selling Shareholders are the owners or holders of
      rights to the common shares in the capital of Priveco as listed in
      Schedule 1;

	 	 
	B. 	
      Pubco has agreed to issue $24,593,000 (the
      “Consideration”) in value of common shares in the capital of Pubco
      (the “Consideration Shares”) as of the Closing Date (as defined
      herein) to the Selling Shareholders as consideration for the purchase by
      Pubco of all of the issued and outstanding common shares of Priveco held
      by the Selling Shareholders (including those shares that could result from
      the conversion of the Convertible Bonds (the "Conversion Shares")
      );

	 	 
	C. 	
      Upon the terms and subject to the conditions set forth in
      this Agreement, the Selling Shareholders have agreed to sell all of the
      issued and outstanding common shares of Priveco held by the Selling
      Shareholders including the Conversion Shares to Pubco in exchange for the
      Consideration Shares.

- 1 - 

Execution version 

THEREFORE, in consideration of the mutual covenants and
agreements herein contained and other good and valuable consideration (the
receipt and sufficiency of which are hereby acknowledged), the parties covenant
and agree as follows: 

	1. 	
      DEFINITIONS

	1.1 	
      Definitions. The following terms have the
      following meanings, unless the context indicates
  otherwise:

	 	(a) 	
      “Agreement” shall mean this Agreement, and all the
      exhibits, schedules and other documents attached to or referred to in this
      Agreement, and all amendments and supplements, if any, to this
      Agreement;

	 	 	 
	 	(b) 	
      “Average Closing Price” means the average of all
      closing trading prices for Pubco’s common shares as traded on the OTC
      stock market for the 30 trading days immediately preceding the Closing
      Date;

	 	 	 
	 	(c) 	
      "Bondholders" means the holders of Convertible
      Bonds;

	 	 	 
	 	(d) 	
      “Closing” shall mean the completion of the
      Transaction, at which the Closing Documents shall be exchanged by the
      parties, except for those documents or other items specifically required
      to be exchanged at a later time;

	 	 	 
	 	(e) 	
      “Closing Date” shall mean a date mutually agreed
      upon by the parties hereto in writing following the satisfaction or waiver
      by Pubco and Priveco of the conditions precedent set out in Sections 5.1
      and 5.2 respectively;

	 	 	 
	 	(f) 	
      “Closing Documents” shall mean the papers,
      instruments and documents required to be executed and delivered at the
      Closing pursuant to this Agreement;

	 	 	 
	 	(g) 	
      “Consideration” means $24,593,000;

	 	 	 
	 	(h) 	
      “Consideration Shares” means the fully paid and
      non-assessable common shares issued on the Closing Date to the Selling
      Shareholders in payment of the Consideration;

	 	 	 
	 	(i) 	
      “Consideration Share Price” has the meaning
      ascribed in section 2.2;

	 	 	 
	 	(j) 	
      "Convertible Bonds" shall mean the bonds
      convertible in MasTHerCell Common Stock issued by MasTHerCell pursuant to
      and subject to the conditions set forth in a notarized decision of the
      general meeting of shareholders of MasTHerCell dated on 18 September 2014,
      as listed in Schedule 1;

	 	 	 
	 	(k) 	
      “Exchange Act” shall mean the United States
      Securities Exchange Act of 1934, as amended;

	 	 	 
	 	(l) 	
      “GAAP” shall mean United States generally accepted
      accounting principles for public company accounting applied in a manner
      consistent with prior periods;

	 	 	 
	 	(m) 	
      “Intellectual Property Assets” has the meaning
      ascribed in section 3.20.

- 2 - 

Execution version 

	 	(n) 	
      “Liabilities” shall include any direct or indirect
      indebtedness, guaranty, endorsement, claim, loss, damage, deficiency,
      cost, expense, obligation or responsibility, fixed or unfixed, known or
      unknown, asserted choate or inchoate, liquidated or unliquidated, secured
      or unsecured;

	 	 	 
	 	(o) 	
      “Priveco” means where the context permits,
      MasTHerCell and CTH;

	 	 	 
	 	(p) 	
      “Priveco Shares” shall mean the common shares of
      Priveco held by the Selling Shareholders as listed in Schedule 1, being
      all of the issued and outstanding common shares of both MasTHerCell and
      CTH, the profit shares issued by CTH and the Conversion Shares
      beneficially held, either directly or indirectly, by the Selling
      Shareholders;

	 	 	 
	 	(q) 	
      “publicly disclosed” means as disclosed in a
      newswire disseminated news release or on EDGAR;

	 	 	 
	 	(r) 	
      “SEC” shall mean the United States Securities and
      Exchange Commission;

	 	 	 
	 	(s) 	
      “SEC Reports” means the forms, reports (including
      reports on Forms 8-K, 10-Q and 10- K), statements (including proxy
      statements), schedules and registration statements of the Pubco, filed or
      furnished by Pubco with the SEC since December 31, 2011 and available on
      the SEC’s EDGAR database.

	 	 	 
	 	(t) 	
      “Securities Act” shall mean the United States
      Securities Act of 1933, as amended;

	 	 	 
	 	(u) 	
      “Taxes” shall include international, federal,
      state, provincial and local income taxes, capital gains tax, value-added
      taxes, franchise, personal property and real property taxes, levies,
      assessments, tariffs, duties (including any customs duty), business
      license or other fees, sales, use and any other taxes relating to the
      assets of the designated party or the business of the designated party for
      all periods up to and including the Closing Date, together with any
      related charge or amount, including interest, fines, penalties and
      additions to tax, if any, arising out of tax assessments; and

	 	 	 
	 	(v) 	
      “Transaction” shall mean the purchase of the
      Priveco Shares by Pubco from the Selling Shareholders in consideration for
      the issuance of the Consideration Shares.

	1.2 	
      Schedules. The following schedules are attached to
      and form part of this Agreement:

	 	1 	–	List of Selling Shareholders 
	 	 	 	 
	 	2A 	– 	Certificate of Non-U.S. Shareholder 
	 	 	 	 
	 	2B 	– 	Certificate of U.S. Shareholder 
	 	 	 	 
	 	3 	– 	Directors of Priveco 
	 	 	 	 
	 	4 	– 	Directors and Officers of Pubco 
	 	 	 	 
	 	5 	– 	Priveco Intellectual Property 
	 	 	 	 
	 	6 	– 	Priveco Material Contracts 
	 	 	 	 
	 	7 	– 	Blank 

- 3 - 

Execution version 

	 	8 	– 	Blank 
	 	9 	–	Escrow Agreement 

	1.3 	
      Currency. All references to currency referred to
      in this Agreement are in United States Dollars (US$), unless expressly
      stated otherwise.

	2. 	
      THE OFFER, PURCHASE AND SALE OF
  SHARES

	2.1 	
      Offer, Purchase and Sale of Shares. Subject to the
      terms and conditions of this Agreement, the Selling Shareholders hereby
      covenant and agree to sell, assign and transfer to Pubco, and Pubco hereby
      covenants and agrees to purchase from the Selling Shareholders all of the
      Priveco Shares held by the Selling Shareholders. For the avoidance of
      doubt, if the Selling Shareholders obtain additional Priveco Shares as a
      result of the conversion of the Convertible Bonds (notably, the Conversion
      Shares by application of section 11 below), such additional Priveco Shares
      shall also be transferred to Pubco for no additional
  consideration.

	 	 
	2.2 	
      Consideration Share Pricing. The Consideration
      Shares will be issued at a deemed price (the “Consideration Share Price”)
      equalling the Average Closing Price, provided that if the Average Closing
      Price is in excess of $0.80, the Consideration Shares will be issued at a
      price of $0.80 per Consideration Share, and if the Average Closing Price
      is below $0.50, the Consideration Shares will be issued at a price of
      $0.50 per Consideration Share.

	 	 
	2.3 	
      Consideration. As consideration for the sale of
      the Priveco Shares by the Selling Shareholders to Pubco (including the
      Conversion Shares), Pubco shall allot and issue the Consideration Shares
      to the Selling Shareholders or their nominees in the amount set out
      opposite each Selling Shareholder’s name in Schedule 1. The Selling
      Shareholders acknowledge and agree that the Consideration Shares are being
      issued pursuant to an exemption from the prospectus and registration
      requirements of the Securities Act. As required by applicable securities
      law, the Selling Shareholders agree to abide by all applicable resale
      restrictions and hold periods imposed by all applicable securities
      legislation. All certificates representing the Consideration Shares issued
      on Closing will be endorsed with the following legend pursuant to the
      Securities Act in order to reflect the fact that the Consideration Shares
      will be issued to the Selling Shareholders pursuant to an exemption from
      the registration requirements of the Securities
Act:

	 	(a) 	
      For Selling Shareholders not resident in the United
      States:

	
      “THE SECURITIES REPRESENTED HEREBY HAVE BEEN OFFERED IN
      AN OFFSHORE TRANSACTION TO A PERSON WHO IS NOT A U.S. PERSON (AS DEFINED
      HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF
      1933, AS AMENDED (THE “1933 ACT”). 

- 4 - 

Execution version 

	
      NONE OF THE SECURITIES REPRESENTED HEREBY HAVE BEEN
      REGISTERED UNDER THE 1933 ACT, OR ANY U.S. STATE SECURITIES LAWS, AND,
      UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY,
      IN THE UNITED STATES (AS DEFINED HEREIN) OR TO U.S. PERSONS EXCEPT IN
      ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT,
      PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 ACT, OR
      PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT
      TO, THE REGISTRATION REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY IN
      ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING
      TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN
      COMPLIANCE WITH THE 1933 ACT. “UNITED STATES” AND “U.S. PERSON” ARE AS
      DEFINED BY REGULATION S UNDER THE 1933 ACT.”

	 	(b) 	
      For Selling Shareholders resident in the United
      States:

	
      “NONE OF THE SECURITIES REPRESENTED HEREBY HAVE BEEN
      REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE
      “1933 ACT”), OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED,
      MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES
      (AS DEFINED HEREIN) OR TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH THE
      PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE
      REGISTRATION STATEMENT UNDER THE 1933 ACT, OR PURSUANT TO AN AVAILABLE
      EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
      REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH
      APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS
      INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH
      THE 1933 ACT. “UNITED STATES” AND “U.S. PERSON” ARE AS DEFINED BY
      REGULATION S UNDER THE 1933 ACT.” 

	2.4 	
      Share Exchange Procedure. Each Selling Shareholder
      will exchange his, her or its Priveco Shares by entering such transfer to
      Pubco in the respective share registers of Priveco, duly executed for the
      benefit of Pubco, in proper form for transfer and with appropriate
      instructions to allow the transfer agent to issue certificates for the
      Consideration Shares to the holder thereof, together
  with:

	 	(a) 	
      if the Selling Shareholder is not resident in the United
      States, a Certificate of Non-U.S. Shareholder (the “Certificate of
      Non-U.S. Shareholder”), a copy of which is set out in Schedule 2A;
      and

- 5 - 

Execution version 

	 	(b) 	
      if the Selling Shareholder is resident in the United
      States, a Certificate of U.S. Shareholder (the “Certificate of U.S.
      Shareholder”), a copy of which is set out in Schedule
  2B.

	2.5 	
      Fractional Shares/Warrants. Notwithstanding any
      other provision of this Agreement, no certificate for fractional shares or
      warrants of the Consideration Shares will be issued in the Transaction. In
      lieu of any such fractional shares or warrants the Selling Shareholders
      would otherwise be entitled to receive upon exchange of the Priveco Shares
      pursuant to this Agreement, the Selling Shareholders will be entitled to
      have such fraction rounded up to the nearest whole number of Consideration
      Shares and will receive from Pubco a stock certificate and warrant
      certificate representing same.

	 	 
	2.6 	
      Closing Date. The Closing will take place, subject
      to the terms and conditions of this Agreement, on the Closing
  Date.

	 	 
	2.7 	
      Restricted Securities. The Selling Shareholders
      acknowledge that the Consideration Shares issued pursuant to the terms and
      conditions set forth in this Agreement will be “restricted securities”
      under the Securities Act and as a result may not be sold, transferred or
      otherwise disposed, except pursuant to an effective registration statement
      under the Securities Act, or pursuant to an exemption from, or in a
      transaction not subject to, the registration requirements of the
      Securities Act and in each case only in accordance with all applicable
      securities laws.

	 	 
	2.8 	
      Additional Restrictions. Escrow. In
      addition to any resale restrictions imposed by law, the Selling
      Shareholders agree not to sell any of their Consideration Shares for a
      period of one (1) year after the Closing, except where such sale takes
      place between Selling Shareholders, and thereafter one twelfth (1/12th) of
      each Selling Shareholders' Consideration Shares shall be released and
      eligible for sale during each subsequent calendar month (the
      "Lock-Up"), giving priority if agreed among Selling Shareholders to
      the release of the Consideration Shares of certain Selling Shareholders as
      directed by the Selling Shareholders in writing. The Consideration Shares
      will be held in escrow by Pubco’s transfer agent (the "Escrow
      Agent") who are irrevocably instructed not to release Consideration
      Shares to the Selling Shareholders (including the Bondholders) and/or, as
      the case may be, Pubco unless in accordance with the Escrow Agreement
      attached hereto as Schedule 9. For the avoidance of doubt, these
      additional restrictions shall not apply to the exchange between the
      Bondholders and the Selling Shareholders of MasTHerCell Common Stock for
      Consideration Shares as set forth in section 11 below, but will apply to
      any Consideration Shares transferred to a former Bondholder. If any
      shareholder of Pubco benefits from shorter or more favourable resale
      restrictions in case of listing of Pubco's shares on NASDAQ or any other
      regulated market, then those shorter or more favourable resale
      restrictions will apply automatically to the Selling Shareholders
      (including, as the case may be, the Bondholders).

- 6 - 

Execution version 

	3. 	
      REPRESENTATIONS AND WARRANTIES OF PRIVECO AND THE
      SELLING SHAREHOLDERS

Priveco and the Selling Shareholders,
severally and not jointly and in proportion to the number of Consideration
Shares received by each of them at any time, represent and warrant to Pubco, and
acknowledge that Pubco is relying upon such representations and warranties, in
connection with the execution, delivery and performance of this Agreement,
notwithstanding any investigation made by or on behalf of Pubco but subject to
any specific disclosure made in writing, and whereby unless stated otherwise
such representations and warranties shall be deemed given at the date hereof and
repeated at Closing as follows: 

	3.1 	
      Organization and Good Standing. Priveco is a
      corporation duly organized, validly existing and in good standing under
      the laws of its jurisdiction of incorporation and has the requisite
      corporate power and authority to own, lease and to carry on its business
      as now being conducted. Priveco is duly qualified to do business and is in
      good standing as a corporation in each of the jurisdictions in which
      Priveco owns property, leases property, does business, or is otherwise
      required to do so, where the failure to be so qualified would have a
      material adverse effect on the business of Priveco taken as a
  whole.

	 	 
	3.2 	
      Authority. Priveco has all requisite corporate
      power and authority to execute and deliver this Agreement and any other
      document contemplated by this Agreement (collectively, the “Priveco
      Documents”) to be signed by Priveco and to perform its obligations
      hereunder and to consummate the transactions contemplated hereby. The
      execution and delivery of each of the Priveco Documents by Priveco and the
      consummation of the transactions contemplated hereby have been duly
      authorized by Priveco’ s boards of directors. No other corporate or
      shareholder proceedings on the part of Priveco is necessary to authorize
      such documents or to consummate the transactions contemplated hereby. This
      Agreement has been, and the other Priveco Documents when executed and
      delivered by Priveco as contemplated by this Agreement will be, duly
      executed and delivered by Priveco and this Agreement is, and the other
      Priveco Documents when executed and delivered by Priveco as contemplated
      hereby will be, valid and binding obligations of Priveco enforceable in
      accordance with their respective terms except:

	 	(a) 	
      as limited by applicable bankruptcy, insolvency,
      reorganization, moratorium, and other laws of general application
      affecting enforcement of creditors’ rights generally;

	 	 	 
	 	(b) 	
      as limited by laws relating to the availability of
      specific performance, injunctive relief, or other equitable remedies;
      and

	 	 	 
	 	(c) 	
      as limited by public policy.

- 7 -

Execution version 

	3.3 	
      Capitalization of MasTHerCell. The entire
      authorized capital stock and other equity securities of MasTHerCell
      consists of 2,400 common shares (the “MasTHerCell Common Stock”).
      As of the date of this Agreement, there are 2,400 shares of
      MasTHerCell Common Stock issued and outstanding and or 1,600 Convertible
      Bonds outstanding. All of the issued and outstanding shares of MasTHerCell
      Common Stock have been duly authorized, are validly issued, were not
      issued in violation of any pre-emptive rights and are fully paid and non-
      assessable, were issued in full compliance with the laws of Belgium. Other
      than as stated in this Agreement, there are no outstanding options,
      warrants, subscriptions, conversion rights, or other rights, agreements,
      or commitments obligating Priveco to issue any additional common shares of
      MasTHerCell Common Stock, or any other securities convertible into,
      exchangeable for, or evidencing the right to subscribe for or acquire from
      Priveco any common shares of MasTHerCell Common Stock. Other than as
      stated in this Agreement, there are no agreements purporting to restrict
      the transfer of the MasTHerCell Common Stock, no voting agreements,
      shareholders’ agreements, voting trusts, or other arrangements restricting
      or affecting the voting of the MasTHerCell Common Stock. To the fullest
      extent necessary, the Selling Shareholders holding MasTHerCell Common
      Stock irrevocably waive the pre-emptive right applicable pursuant to
      article 10 of MasTHerCell's articles of association and waive any
      notification obligation applying under any shareholder agreement between
      them in the context of the transactions contemplated in this
    Agreement.

	 	 
	3.4 	
      Capitalization of CTH. The entire authorized
      capital stock and other equity securities of CTH consists of 1,224 common
      shares (the “CTH Common Stock”). As of the date of this Agreement,
      there are 1,224 shares of CTH Common Stock issued and outstanding and 600
      profit shares outstanding. All of the issued and outstanding shares of CTH
      Common Stock and the profit shares have been duly authorized, are validly
      issued, were not issued in violation of any pre-emptive rights and are
      fully paid and non-assessable and were issued in full compliance with the
      laws of Belgium. Other than as stated in this Agreement, there are no
      outstanding options, warrants, subscriptions, conversion rights, or other
      rights, agreements, or commitments obligating CTH to issue any additional
      common shares of CTH Common Stock, or any other securities convertible
      into, exchangeable for, or evidencing the right to subscribe for or
      acquire from CTH any common shares of CTH Common Stock. Other than as
      stated in this Agreement, there are no agreements purporting to restrict
      the transfer of the CTH Common Stock, no voting agreements, shareholders’
      agreements, voting trusts, or other arrangements restricting or affecting
      the voting of the CTH Common Stock. To the fullest extent necessary, the
      Selling Shareholders holding CTH common stock irrevocably waive the
      pre-emptive right applicable pursuant to article 10 of CTH's articles of
      association and waive any notification obligation applying under any
      shareholder agreement between them in the context of the transactions
      contemplated in this Agreement.

	 	 
	3.5 	
      Title and Authority of Selling Shareholders. Each
      of the Selling Shareholders is and will be as of the Closing, the
      beneficial owner of and will have good and marketable title to all of the
      Priveco Shares held by it and will hold such free and clear of all liens,
      charges and encumbrances whatsoever; and such Priveco Shares held by such
      Selling Shareholders have been duly and validly issued and are outstanding
      as fully paid and non-assessable common shares in the capital of Priveco.
      Each of the Selling Shareholders has due and sufficient right and
      authority to enter into this Agreement on the terms and conditions herein
      set forth and to transfer the registered, legal and beneficial title and
      ownership of the Priveco Shares held by it.

- 8 - 

Execution version 

	3.6 	
      Shareholders of Priveco Shares. Schedule 1
      contains a true and complete list of the holders of all rights to acquire
      shares of the Priveco Shares including each holder’s name, address and
      number of rights to Priveco Shares held.

	 	 
	3.7 	
      Directors and Officers of Priveco. The duly
      elected or appointed directors and the duly appointed officers of Priveco
      are as set out in Schedule 3.

	 	 
	3.8 	
      Corporate Records of Priveco. The corporate
      records of Priveco, as required to be maintained by it pursuant to all
      applicable laws, are accurate, complete and current in all material
      respects, and the minute book of Priveco is, in all material respects,
      correct and contains all records required by all applicable laws, as
      applicable, in regards to all proceedings, consents, actions and meetings
      of the shareholders and the board of directors of Priveco.

	 	 
	3.9 	
      Non-Contravention. Neither the execution, delivery
      and performance of this Agreement, nor the consummation of the
      Transaction, will:

	 	(a) 	
      conflict with, result in a violation of, cause a default
      under (with or without notice, lapse of time or both) or give rise to a
      right of termination, amendment, cancellation or acceleration of any
      obligation contained in or the loss of any material benefit under, or
      result in the creation of any lien, security interest, charge or
      encumbrance upon any of the material properties or assets of Priveco or
      any of its subsidiaries under any term, condition or provision of any loan
      or credit agreement, note, debenture, bond, mortgage, indenture, lease or
      other agreement, instrument, permit, license, judgment, order, decree,
      statute, law, ordinance, rule or regulation applicable to Priveco or any
      of its subsidiaries, or any of their respective material property or
      assets;

	 	 	 
	 	(b) 	
      violate any provision of the constituting documents of
      Priveco, any of its subsidiaries or any applicable laws; or

	 	 	 
	 	(c) 	
      violate any order, writ, injunction, decree, statute,
      rule, or regulation of any court or governmental or regulatory authority
      applicable to Priveco, any of its subsidiaries or any of their respective
      material property or assets.

	3.10 	
      Actions and Proceedings. To the best knowledge of
      Priveco, there is no basis for and there is no action, suit, judgment,
      claim, demand or proceeding outstanding or pending, or threatened against
      or affecting Priveco, any of its subsidiaries or which involves any of the
      business, or the properties or assets of Priveco or any of its
      subsidiaries that, if adversely resolved or determined, would have a
      material adverse effect on the business, operations, assets, properties,
      prospects, or conditions of Priveco and its subsidiaries taken as a whole
      (a “Priveco Material Adverse Effect”). There is no reasonable basis
      for any claim or action that, based upon the likelihood of its being
      asserted and its success if asserted, would have such a Priveco Material
      Adverse Effect.

- 9 - 

Execution version 

	3.11 	
      Compliance.

	 	(a) 	
      To the best knowledge of Priveco, Priveco and each of its
      subsidiaries is in compliance with, is not in default or violation in any
      material respect under, and has not been charged with or received any
      notice at any time of any material violation of any statute, law,
      ordinance, regulation, rule, decree or other applicable regulation to the
      business or operations of Priveco and its subsidiaries that could
      reasonably be expected to result in a Priveco Material Adverse
    Effect;

	 	 	 
	 	(b) 	
      To the best knowledge of Priveco, neither Priveco nor any
      of its subsidiaries is subject to any judgment, order or decree entered in
      any lawsuit or proceeding applicable to its business and operations that
      would constitute a Priveco Material Adverse Effect;

	 	 	 
	 	(c) 	
      Each of Priveco and its subsidiaries has duly filed all
      reports and returns required to be filed by it with governmental
      authorities and has obtained all governmental permits and other
      governmental consents, except as may be required after the execution of
      this Agreement. All of such permits and consents are in full force and
      effect, and no proceedings for the suspension or cancellation of any of
      them, and no investigation relating to any of them, is pending or to the
      best knowledge of Priveco, threatened, and none of them will be adversely
      affected by the consummation of the Transaction; and

	 	 	 
	 	(d) 	
      Each of Priveco and its subsidiaries has operated in
      material compliance with all laws, rules, statutes, ordinances, orders and
      regulations applicable to its business. Neither Priveco nor any of its
      subsidiaries has received any notice of any violation thereof, nor is
      Priveco aware of any valid basis therefore.

	3.12 	
      Filings, Consents and Approvals. No filing or
      registration with, no notice to and no permit, authorization, consent, or
      approval of any public or governmental body or authority or other person
      or entity is necessary for the consummation by Priveco or any of its
      subsidiaries of the Transaction contemplated by this Agreement or to
      enable Pubco to continue to conduct Priveco’s business after the Closing
      Date in a manner which is consistent with that in which the business is
      presently conducted.

	 	 
	3.13 	
      Financial Representations. At the latest at
      Closing each of MasTHerCell and CTH shall deliver true, correct, and
      complete copies of the consolidated audited financial statements for such
      company dated as of their most recently completed fiscal year ends (which
      MasTHerCell and CTH warrant will be dated December 31, 2013) and a
      consolidated auditor reviewed financial statement with respect to the
      current fiscal year to 31 August 2014 (the “Priveco Accounting Date”),
      together with related balance sheets, statements of income, cash
      flows, and changes in shareholder’s equity for such fiscal years and
      interim period then ended (collectively, the “Priveco Financial
      Statements”). The Priveco Financial Statements will
  be:

	 	(a) 	
      in accordance with the books and records of
    Priveco;

	 	 	 
	 	(b) 	
      present fairly the financial condition of Priveco as of
      the respective dates indicated and the results of operations for such
      periods;

	 	 	 
	 	(c) 	
      have been prepared in accordance with GAAP;
  and

- 10 - 

Execution version 

	 	(d) 	
      the audit and the review will be prepared by independent
      certified public accountants who are one of KPMG, Deloittes, PWC or E
      &Y and which is registered with the United States Public Company
      Accounting Oversight Board.

Priveco has not received any advice or
notification from its independent certified public accountants that Priveco has
used any improper accounting practice that would have the effect of not
reflecting or incorrectly reflecting in the Priveco Financial Statements or the
books and records of Priveco, any properties, assets, Liabilities, revenues, or
expenses. The books, records, and accounts of Priveco accurately and fairly
reflect, in reasonable detail, the assets, and Liabilities of Priveco. Priveco
has not engaged in any transaction, maintained any bank account, or used any
funds of Priveco, except for transactions, bank accounts, and funds which have
been and are reflected in the normally maintained books and records of Priveco.

	3.14 	
      Absence of Undisclosed Liabilities. Neither
      Priveco nor any of its subsidiaries has any material Liabilities or
      obligations either direct or indirect, matured or unmatured, absolute,
      contingent or otherwise that exceed $50,000,
which:

	 	(a) 	
      will not be set forth in the Priveco Financial Statements
      or have not heretofore been paid or discharged;

	 	 	 
	 	(b) 	
      did not arise in the regular and ordinary course of
      business under any agreement, contract, commitment, lease or plan
      specifically disclosed in writing to Pubco; or

	 	 	 
	 	(c) 	
      have not been incurred in amounts and pursuant to
      practices consistent with past business practice, in or as a result of the
      regular and ordinary course of its business since Priveco Accounting
      Date.

	3.15 	
      Tax Matters.

As of the date hereof: 

	 	(a) 	
      each of Priveco and its subsidiaries has timely filed all
      tax returns in connection with any Taxes which are required to be filed on
      or prior to the date hereof, taking into account any extensions of the
      filing deadlines which have been validly granted to Priveco or its
      subsidiaries, and all such returns are true and correct in all material
      respects;

	 	 	 
	 	(b) 	
      each of Priveco and its subsidiaries has paid all Taxes
      that have become or are due with respect to any period ended on or prior
      to the date hereof, and has established an adequate reserve therefore on
      its balance sheets for those Taxes not yet due and payable, except for any
      Taxes the non-payment of which will not have a Priveco Material Adverse
      Effect;

	 	 	 
	 	(c) 	
      neither Priveco nor any of its subsidiaries is presently
      under or has received notice of, any contemplated investigation or audit
      by regulatory or governmental agency of body or any foreign or state
      taxing authority concerning any fiscal year or period ended prior to the
      date hereof;

- 11 - 

Execution version 

	 	(d) 	
      all Taxes required to be withheld on or prior to the date
      hereof from employees for income Taxes, social security Taxes,
      unemployment Taxes and other similar withholding Taxes have been properly
      withheld and, if required on or prior to the date hereof, have been
      deposited with the appropriate governmental agency; and

	 	 	 
	 	(e) 	
      to the best knowledge of Priveco, the Priveco Financial
      Statements will contain full provision for all Taxes including any
      deferred Taxes that may be assessed to Priveco or its subsidiaries for the
      accounting period ended on the Priveco Accounting Date or for any prior
      period in respect of any transaction, event or omission occurring, or any
      profit earned, on or prior to the Priveco Accounting Date or for any
      profit earned by Priveco on or prior to the Priveco Accounting Date or for
      which Priveco is accountable up to such date and all contingent
      Liabilities for Taxes have been provided for or disclosed in the Priveco
      Financial Statements.

	3.16 	
      Absence of Changes. From the date of execution of
      this Agreement to the Closing Date, neither Priveco or any of its
      subsidiaries will have:

	 	(a) 	
      incurred any Liabilities, other than Liabilities incurred
      in the ordinary course of business consistent with past practice, or
      discharged or satisfied any lien or encumbrance, or paid any Liabilities,
      other than in the ordinary course of business consistent with past
      practice, or failed to pay or discharge when due any Liabilities of which
      the failure to pay or discharge has caused or will cause any material
      damage or risk of material loss to it or any of its assets or
      properties;

	 	 	 
	 	(b) 	
      sold, encumbered, assigned or transferred any material
      fixed assets or properties except for ordinary course business
      transactions consistent with past practice;

	 	 	 
	 	(c) 	
      created, incurred, assumed or guaranteed any indebtedness
      for money borrowed, or mortgaged, pledged or subjected any of the material
      assets or properties of Priveco or its subsidiaries to any mortgage, lien,
      pledge, security interest, conditional sales contract or other encumbrance
      of any nature whatsoever;

	 	 	 
	 	(d) 	
      made or suffered any amendment or termination of any
      material agreement, contract, commitment, lease or plan to which it is a
      party or by which it is bound, or cancelled, modified or waived any
      substantial debts or claims held by it or waived any rights of substantial
      value, other than in the ordinary course of business;

	 	 	 
	 	(e) 	
      declared, set aside or paid any dividend or made or
      agreed to make any other distribution or payment in respect of its capital
      shares or redeemed, purchased or otherwise acquired or agreed to redeem,
      purchase or acquire any of its capital shares or equity
  securities;

	 	 	 
	 	(f) 	
      suffered any damage, destruction or loss, whether or not
      covered by insurance, that materially and adversely effects its business,
      operations, assets, properties or prospects;

	 	 	 
	 	(g) 	
      suffered any material adverse change in its business,
      operations, assets, properties, prospects or condition (financial or
      otherwise);

- 12 - 

Execution version 

	 	(h) 	
      received notice or had knowledge of any actual or
      threatened labour trouble, termination, resignation, strike or other
      occurrence, event or condition of any similar character which has had or
      would reasonably be expected to result in a Priveco Material Adverse
      Effect ;

	 	 	 
	 	(i) 	
      made commitments or agreements for capital expenditures
      or capital additions or betterments exceeding in the aggregate
    $50,000;

	 	 	 
	 	(j) 	
      other than in the ordinary course of business, increased
      the salaries or other compensation of, or made any advance (excluding
      advances for ordinary and necessary business expenses) or loan to, any of
      its employees or directors or made any increase in, or any addition to,
      other benefits to which any of its employees or directors may be
      entitled;

	 	 	 
	 	(k) 	
      entered into any transaction other than in the ordinary
      course of business consistent with past practice; or

	 	 	 
	 	(l) 	
      agreed, whether in writing or orally, to do any of the
      foregoing.

	3.17 	
      Absence of Certain Changes or Events. From the
      date of execution of this Agreement to the Closing Date, there will have
      not been:

	 	(a) 	
      a Priveco Material Adverse Effect; or

	 	 	 
	 	(b) 	
      any material change by Priveco in its accounting methods,
      principles or practices.

	3.18 	
      Subsidiaries. Except as set forth in writing,
      Priveco does not have any subsidiaries or agreements of any nature to
      acquire any subsidiary or to acquire or lease any other business
      operations. Each subsidiary of Priveco is a corporation duly organized,
      validly existing and in good standing under the laws of its jurisdiction
      of incorporation and has the requisite corporate power and authority to
      own, lease and to carry on its business as now being conducted. Each
      subsidiary of Priveco is duly qualified to do business and is in good
      standing as a corporation in each of the jurisdictions in which Priveco
      owns property, leases property, does business, or is otherwise required to
      do so, where the failure to be so qualified would have a Priveco Material
      Adverse Effect. Priveco owns all of the shares of each subsidiary of
      Priveco and there are no outstanding options, warrants, subscriptions,
      conversion rights, or other rights, agreements, or commitments obligating
      any subsidiary of Priveco to issue any additional common shares of such
      subsidiary, or any other securities convertible into, exchangeable for, or
      evidencing the right to subscribe for or acquire from any subsidiary of
      Priveco any shares of such subsidiary.

	 	 
	3.19 	
      Personal Property. Each of Priveco and its
      subsidiaries possesses, and has good and marketable title of all property
      necessary for the continued operation of the business of Priveco and its
      subsidiaries as presently conducted and as represented to Pubco. All such
      property is used in the business of Priveco and its subsidiaries. All such
      property is in reasonably good operating condition (normal wear and tear
      excepted), and is reasonably fit for the purposes for which such property
      is presently used. All material equipment, furniture, fixtures and other
      tangible personal property and assets owned or leased by Priveco and its
      subsidiaries is owned by Priveco or its subsidiaries free and clear of all
      liens, security interests, charges, encumbrances, and other adverse
      claims.

- 13 - 

Execution version 

	3.20 	
      Intellectual Property Assets. Priveco and its
      subsidiaries own or hold an interest (including by way of a licence) in
      all intellectual property assets necessary for the operation of the
      business of Priveco and its subsidiaries as it is currently conducted
      (collectively, the “Intellectual Property Assets”),
    including:

	 	(a) 	
      all functional business names, trading names, registered
      and unregistered trademarks, service marks, and applications
      (collectively, the “Marks”);

	 	 	 
	 	(b) 	
      all patents, patent applications, and inventions,
      methods, processes and discoveries that may be patentable (collectively,
      the “Patents”);

	 	 	 
	 	(c) 	
      all copyrights in both published works and unpublished
      works (collectively, the “Copyrights”); and

	 	 	 
	 	(d) 	
      all know-how, trade secrets, confidential information,
      customer lists, software, technical information, data, process technology,
      plans, drawings, and blue prints owned, used, or licensed by Priveco and
      its subsidiaries as licensee or licensor (collectively, the “Trade
      Secrets”).

	3.21 	
      Priveco Intellectual Property. A full list of all
      registered Priveco Intellectual Property Assets is included on Schedule 5
      of this Agreement.

	 	 
	3.22 	
      Employees and Consultants. All employees and
      consultants of Priveco and its subsidiaries have been paid all salaries,
      wages, income and any other sum due and owing to them by Priveco or its
      subsidiaries, as at the end of the most recent completed pay period.
      Neither Priveco nor any of its subsidiaries is aware of any labor conflict
      with any employees that might reasonably be expected to have a Priveco
      Material Adverse Effect. To the best knowledge of Priveco, no employee of
      Priveco or any of its subsidiaries is in violation of any term of any
      employment contract, nondisclosure agreement, non-competition agreement or
      any other contract or agreement relating to the relationship of such
      employee with Priveco or its subsidiaries or any other nature of the
      business conducted or to be conducted by Priveco its
  subsidiaries.

	 	 
	3.23 	
      Real Property. Neither Priveco nor any of its
      subsidiaries owns any real property. Each of the leases, subleases, claims
      or other real property interests (collectively, the “Leases”) to
      which Priveco or any of its subsidiaries is a party or is bound is legal,
      valid, binding, enforceable and in full force and effect in all material
      respects. All rental and other payments required to be paid by Priveco and
      its subsidiaries pursuant to any such Leases have been duly paid and no
      event has occurred which, upon the passing of time, the giving of notice,
      or both, would constitute a breach or default by any party under any of
      the Leases. The Leases will continue to be legal, valid, binding,
      enforceable and in full force and effect on identical terms following the
      Closing Date. Neither Priveco nor any of its subsidiaries has assigned,
      transferred, conveyed, mortgaged, deeded in trust, or encumbered any
      interest in the Leases or the leasehold property pursuant
  thereto.

	 	 
	3.24 	
      Certain Transactions. Neither Priveco nor any of
      its subsidiaries is a guarantor or indemnitor of any indebtedness of any
      third party, including any person, firm or
corporation.

- 14 - 

Execution version 

	3.25 	
      No Brokers. Neither Priveco nor any of its
      subsidiaries has incurred any independent obligation or liability to any
      party for any brokerage fees, agent’s commissions, or finder’s fees in
      connection with the Transaction contemplated by this Agreement.

	 	 
	3.26 	
      Completeness of Disclosure. No representation or
      warranty by Priveco in this Agreement nor any certificate, schedule,
      statement, document or instrument furnished or to be furnished to Pubco
      pursuant hereto contains or will contain any intentionally untrue
      statement of a material fact or omits or will omit intentionally to state
      a material fact required to be stated herein or therein or necessary to
      make any statement herein or therein not materially misleading.

	 	 
	3.27 	
      Material Contracts and Transactions. Other than
      the Priveco Material Contracts identified on Schedule 6, there are no
      material contracts, agreements, licenses, permits, arrangements,
      commitments, instruments, understandings or contracts, whether written or
      oral, express or implied, contingent, fixed or otherwise, to which Priveco
      is a party except as disclosed in writing to Pubco. The Priveco Material
      Contracts are valid, in full force and effect, and there has been no
      material breach by Priveco and, to the best knowledge of Priveco by any
      other party to the Priveco Material Contracts except as disclosed in
      writing to Pubco.

	4. 	
      REPRESENTATIONS AND WARRANTIES OF
  PUBCO

Pubco represents and warrants to
Priveco and the Selling Shareholders and acknowledges that Priveco and the
Selling Shareholders are relying upon such representations and warranties in
connection with the execution, delivery and performance of this Agreement,
notwithstanding any investigation made by or on behalf of Priveco or the Selling
Shareholders, whereby unless stated otherwise such representations and
warranties shall be deemed given at the date hereof and repeated at Closing, as
follows: 

	4.1 	
      Organization and Good Standing. Pubco is duly
      incorporated, organized, validly existing and in good standing under the
      laws of the State of Nevada and has all requisite corporate power and
      authority to own, lease and to carry on its business as now being
      conducted. Pubco is qualified to do business and is in good standing as a
      foreign corporation in each of the jurisdictions in which it owns
      property, leases property, does business, or is otherwise required to do
      so, where the failure to be so qualified would have a material adverse
      effect on the businesses, operations, or financial condition of
    Pubco.

	 	 
	4.2 	
      Authority. Pubco has all requisite corporate power
      and authority to execute and deliver this Agreement and any other document
      contemplated by this Agreement (collectively, the “Pubco Documents”)
      to be signed by Pubco and to perform its obligations hereunder and to
      consummate the transactions contemplated hereby. The execution and
      delivery of each of the Pubco Documents by Pubco and the consummation by
      Pubco of the transactions contemplated hereby have been duly authorized by
      its board of directors and no other corporate or shareholder proceedings
      on the part of Pubco is necessary to authorize such documents or to
      consummate the transactions contemplated hereby. This Agreement has been,
      and the other Pubco Documents when executed and delivered by Pubco as
      contemplated by this Agreement will be, duly executed and delivered by
      Pubco and this Agreement is, and the other Pubco Documents when executed
      and delivered by Pubco, as contemplated hereby will be, valid and binding
      obligations of Pubco enforceable in accordance with their respective
      terms, except:

- 15 - 

Execution version 

	 	(a) 	
      as limited by applicable bankruptcy, insolvency,
      reorganization, moratorium, and other laws of general application
      affecting enforcement of creditors’ rights generally;

	 	 	 
	 	(b) 	
      as limited by laws relating to the availability of
      specific performance, injunctive relief, or other equitable remedies;
      and

	 	 	 
	 	(c) 	
      as limited by public policy.

	4.3 	
      Capitalization of Pubco. The entire authorized
      capital stock and other equity securities of Pubco consists of
      1,750,000,000 shares of common stock with a par value of $0.0001 (the
      “Pubco Common Stock”). There are 54,744,914 shares of Pubco Common
      Stock issued and outstanding. All of the issued and outstanding shares of
      Pubco Common Stock have been duly authorized, are validly issued, were not
      issued in violation of any pre-emptive rights and are fully paid and
      non-assessable, are not subject to pre-emptive rights and were issued in
      full compliance with all federal, state, and local laws, rules and
      regulations. Except as publicly disclosed, there are no outstanding
      options, warrants, subscriptions, phantom shares, conversion rights, or
      other rights, agreements, or commitments obligating Pubco to issue any
      additional shares of Pubco Common Stock, or any other securities
      convertible into, exchangeable for, or evidencing the right to subscribe
      for or acquire from Pubco any shares of Pubco Common Stock as of the date
      of this Agreement. There are no agreements purporting to restrict the
      transfer of the Pubco Common Stock, no voting agreements, voting trusts,
      or other arrangements restricting or affecting the voting of the Pubco
      Common Stock.

	 	 
	4.4 	
      Directors and Officers of Pubco. The duly elected
      or appointed directors and the duly appointed officers of Pubco are as
      listed on Schedule 4.

	 	 
	4.5 	
      Corporate Records of Pubco. The corporate records
      of Pubco, as required to be maintained by it pursuant to the laws of the
      State of Nevada, are accurate, complete and current in all material
      respects, and the minute book of Pubco is, in all material respects,
      correct and contains all material records required by the law of the State
      of Nevada in regards to all proceedings, consents, actions and meetings of
      the shareholders and the board of directors of Pubco.

	 	 
	4.6 	
      Non-Contravention. Neither the execution, delivery
      and performance of this Agreement, nor the consummation of the
      Transaction, will:

	 	(a) 	
      conflict with, result in a violation of, cause a default
      under (with or without notice, lapse of time or both) or give rise to a
      right of termination, amendment, cancellation or acceleration of any
      obligation contained in or the loss of any material benefit under, or
      result in the creation of any lien, security interest, charge or
      encumbrance upon any of the material properties or assets of Pubco under
      any term, condition or provision of any loan or credit agreement, note,
      debenture, bond, mortgage, indenture, lease or other agreement,
      instrument, permit, license, judgment, order, decree, statute, law,
      ordinance, rule or regulation applicable to Pubco or any of its material
      property or assets;

	 	 	 
	 	(b) 	
      violate any provision of the applicable incorporation or
      charter documents of Pubco; or

- 16 - 

Execution version 

	 	(c) 	
      violate any order, writ, injunction, decree, statute,
      rule, or regulation of any court or governmental or regulatory authority
      applicable to Pubco or any of its material property or
  assets.

	4.7 	
      Validity of Pubco Common Stock Issuable upon the
      Transaction. The Consideration Shares to be issued to the Selling
      Shareholders upon consummation of the Transaction in accordance with this
      Agreement will, upon issuance, have been duly and validly authorized and,
      when so issued in accordance with the terms of this Agreement, will be
      duly and validly issued, fully paid and non-assessable. The Consideration
      Shares will entitle their holders to the same rights and obligations as
      all other shares of Pubco Common Stock.

	 	 
	4.8 	
      Actions and Proceedings. Except as publicly
      disclosed, there is no claim, charge, arbitration, grievance, action,
      suit, investigation or proceeding by or before any court, arbiter,
      administrative agency or other governmental authority now pending or, to
      the best knowledge of Pubco, threatened against Pubco or any of its
      subsidiaries which involves any of the business, or the properties or
      assets of Pubco or any of its subsidiaries that, if adversely resolved or
      determined, would have a material adverse effect on the business,
      operations, assets, properties, prospects or conditions of Pubco taken as
      a whole (a “Pubco Material Adverse Effect”). There is no reasonable
      basis for any claim or action that, based upon the likelihood of its being
      asserted and its success if asserted, would have such a Pubco Material
      Adverse Effect.

	4.9 	
      Compliance.

	 	(a) 	
      To the best knowledge of Pubco, Pubco and each of its
      subsidiaries are is in compliance with, is not in default or violation in
      any material respect under, and has not been charged with or received any
      notice at any time of any material violation of any statute, law,
      ordinance, regulation, rule, decree or other applicable regulation to the
      business or operations of Pubco and its subsidiaries;

	 	 	 
	 	(b) 	
      To the best knowledge of Pubco, neither Pubco nor any of
      its subsidiaries is subject to any judgment, order or decree entered in
      any lawsuit or proceeding applicable to its business and operations that
      would constitute a Pubco Material Adverse Effect;

	 	 	 
	 	(c) 	
      Each of Pubco and its subsidiaries has duly filed all
      reports and returns required to be filed by it with governmental
      authorities and has obtained all governmental permits and other
      governmental consents, except as may be required after the execution of
      this Agreement. All of such permits and consents are in full force and
      effect, and no proceedings for the suspension or cancellation of any of
      them, and no investigation relating to any of them, is pending or to the
      best knowledge of Pubco, threatened, and none of them will be affected in
      a material adverse manner by the consummation of the Transaction;
    and

	 	 	 
	 	(d) 	
      Each of Pubco and its subsidiaries has operated in
      material compliance with all laws, rules, statutes, ordinances, orders and
      regulations applicable to its business. Neither Pubco nor any of its
      subsidiaries has received any notice of any violation thereof, nor is
      Pubco aware of any valid basis therefore.

- 17 - 

Execution version 

	4.10 	
      Filings, Consents and Approvals. No filing or
      registration with, no notice to and no permit, authorization, consent, or
      approval of any public or governmental body or authority or other person
      or entity is necessary for the consummation by Pubco of the Transaction
      contemplated by this Agreement to continue to conduct its business after
      the Closing Date in a manner which is consistent with that in which it is
      presently conducted.

	 	 
	4.11 	
      SEC Filings. Pubco has timely filed with or
      furnished to, as applicable, all SEC Reports and other documents required
      to be filed or furnished by the Company with the SEC since December 31,
      2011 together with all exhibits and schedules to the foregoing materials.
      As of their respective filing dates (or, if amended or superseded by a
      subsequent filing, as of the date of the last such amendment or
      superseding filing prior to the date of this Agreement), each SEC Report
      complied in all material respects with the applicable requirements of the
      Securities Act, the Exchange Act, the Sarbanes-Oxley Act of 2002, as
      amended ("Sarbanes- Oxley Act") and the rules and regulations of the SEC
      thereunder applicable to such SEC Report. None of the Company SEC Reports,
      including any financial statements, schedules or exhibits included or
      incorporated by reference therein at the time they were filed (or, if
      amended or superseded by a subsequent filing, as of the date of the last
      such amendment or superseding filing prior to the date of this Agreement),
      contained any untrue statement of a material fact or omitted to state a
      material fact required to be stated therein or necessary in order to make
      the statements therein, in light of the circumstances under which they
      were made, not misleading. There are no outstanding or unresolved comments
      in comment letters from the SEC staff with respect to any of the SEC
      Reports. To Pubco’s best knowledge, none of the SEC Reports is the subject
      of ongoing SEC review or outstanding SEC investigation.

	 	 
	4.12 	
      Financial Statements. Each of the consolidated
      financial statements (including, in each case, any related notes thereto)
      contained in or incorporated by reference into the SEC Reports: (i) have
      been prepared in a manner consistent with the books and records of Pubco;
      (ii) complied as to form in all material respects with applicable
      accounting requirements and the published rules and regulations of the SEC
      with respect thereto as of their respective dates; (iii) was prepared in
      accordance with GAAP (except as may be indicated in the notes thereto and,
      in the case of unaudited interim financial statements, as may be permitted
      by the SEC for Quarterly Reports on Form 10-Q) applied on a consistent
      basis during the period involved; and (iv) fairly presented in all
      material respects the consolidated financial position of Pubco and its
      consolidated subsidiaries at the respective dates thereof and the
      consolidated results of the Company's and its consolidated subsidiaries'
      operations and cash flows for the periods indicated therein, subject, in
      the case of unaudited interim financial statements, to normal and
      recurring year-end audit adjustments that were not, or are not expected to
      be, material in amount, all in accordance with GAAP and the applicable
      rules and regulations of the SEC.

- 18 - 

Execution version 

	4.13 	
      Internal Controls over Financial Reporting. There
      are no, and no disclosure has been made prior to the date of this
      Agreement to the Independent Accounting Firm or Audit Committee of the
      Company Board of any, (i) significant deficiencies or material weaknesses
      in the design or operation of the Company's internal control over
      financial reporting (as defined in Rule 13a-15(f) of the Exchange Act)
      which are reasonably likely to adversely affect the Pubco’s ability to
      record, process, summarize and report financial data or (ii) instances of
      fraud, whether or not material, that involves management or other
      employees who have a role in the Pubco’s internal control over financial
      reporting. Since December 31, 2011, (i) neither Pubco nor, Pubco’s best
      knowledge, any director, officer, employee, auditor, accountant or
      representative of Pubco or any consolidated subsidiary has received or
      otherwise had or obtained knowledge of any material complaint, allegation,
      assertion or claim, whether written or oral, regarding the accounting or
      auditing practices, procedures, methodologies or methods of Pubco or any
      of its subsidiaries or their respective internal accounting controls,
      including any material complaint, allegation, assertion or claim that
      Pubco or any of its subsidiaries has engaged in questionable accounting or
      auditing practices and (ii) no attorney representing Pubco or any of its
      subsidiaries, whether or not employed by Pubco or any of its subsidiaries,
      has reported evidence of a material violation of securities laws, breach
      of fiduciary duty or similar violation by Pubco or any of its subsidiaries
      or any of their respective officers, directors, employees or agents to the
      Pubco Board of Directors or any committee thereof or to any director or
      officer of Pubco or any of its subsidiaries.

	 	 
	4.14 	
      Absence of Undisclosed Liabilities. Except as
      publicly disclosed, neither Pubco nor any of its subsidiaries has material
      Liabilities or obligations either direct or indirect, matured or
      unmatured, absolute, contingent or otherwise,
which:

	 	(a) 	
      did not arise in the regular and ordinary course of
      business under any agreement, contract, commitment, lease or plan
      specifically disclosed in writing to Priveco; or

	 	 	 
	 	(b) 	
      have not been incurred in amounts and pursuant to
      practices consistent with past business practice, in or as a result of the
      regular and ordinary course of its business.

	4.15 	
      Tax Matters.

As of the date hereof and at Closing: 

	 	(a) 	
      Each of Pubco and its subsidiaries has timely filed all
      tax returns in connection with any Taxes which are required to be filed on
      or prior to the date hereof, taking into account any extensions of the
      filing deadlines which have been validly granted to them, and all such
      returns are true and correct in all material respects;

	 	 	 
	 	(b) 	
      Each of Pubco and its subsidiaries has paid all Taxes
      that have become or are due with respect to any period ended on or prior
      to the date hereof;

	 	 	 
	 	(c) 	
      Neither Pubco nor any of its subsidiaries is presently
      under or has received notice of, any contemplated investigation or audit
      by the Internal Revenue Service or any foreign or state taxing authority
      concerning any fiscal year or period ended prior to the date hereof;
      and

- 19 - 

Execution version 

	 	(d) 	
      All Taxes required to be withheld on or prior to the date
      hereof from employees for income Taxes, social security Taxes,
      unemployment Taxes and other similar withholding Taxes have been properly
      withheld and, if required on or prior to the date hereof, have been
      deposited with the appropriate governmental
agency

	4.16 	
      No liabilities. Except as publicly disclosed,
      Pubco has no liabilities or obligations except those incurred in the
      ordinary course of business.

	 	 
	4.17 	
      Absence of Changes. Except as contemplated in this
      Agreement or as publicly disclosed, Pubco has
not:

	 	(a) 	
      incurred any Liabilities, other than Liabilities incurred
      in the ordinary course of business consistent with past practice, or
      discharged or satisfied any lien or encumbrance, or paid any Liabilities,
      other than in the ordinary course of business consistent with past
      practice, or failed to pay or discharge when due any Liabilities of which
      the failure to pay or discharge has caused or will cause any material
      damage or risk of material loss to it or any of its assets or
      properties;

	 	 	 
	 	(b) 	
      sold, encumbered, assigned or transferred any material
      fixed assets or properties;

	 	 	 
	 	(c) 	
      created, incurred, assumed or guaranteed any indebtedness
      for money borrowed, or mortgaged, pledged or subjected any of the material
      assets or properties of Pubco to any mortgage, lien, pledge, security
      interest, conditional sales contract or other encumbrance of any nature
      whatsoever;

	 	 	 
	 	(d) 	
      made or suffered any amendment or termination of any
      material agreement, contract, commitment, lease or plan to which it is a
      party or by which it is bound, or cancelled, modified or waived any
      substantial debts or claims held by it or waived any rights of substantial
      value, other than in the ordinary course of business;

	 	 	 
	 	(e) 	
      declared, set aside or paid any dividend or made or
      agreed to make any other distribution or payment in respect of its capital
      shares or redeemed, purchased or otherwise acquired or agreed to redeem,
      purchase or acquire any of its capital shares or equity
  securities;

	 	 	 
	 	(f) 	
      suffered any damage, destruction or loss, whether or not
      covered by insurance, that materially and adversely effects its business,
      operations, assets, properties or prospects;

	 	 	 
	 	(g) 	
      suffered any material adverse change in its business,
      operations, assets, properties, prospects or condition (financial or
      otherwise);

	 	 	 
	 	(h) 	
      received notice or had knowledge of any actual or
      threatened labor trouble, termination, resignation, strike or other
      occurrence, event or condition of any similar character which has had or
      might have an adverse effect on its business, operations, assets,
      properties or prospects;

	 	 	 
	 	(i) 	
      made commitments or agreements for capital expenditures
      or capital additions or betterments exceeding in the aggregate
    $50,000;

- 20 - 

Execution version 

	 	(j) 	
      other than in the ordinary course of business, increased
      the salaries or other compensation of, or made any advance (excluding
      advances for ordinary and necessary business expenses) or loan to, any of
      its employees or directors or made any increase in, or any addition to,
      other benefits to which any of its employees or directors may be
      entitled;

	 	 	 
	 	(k) 	
      entered into any transaction other than in the ordinary
      course of business consistent with past practice; or

	 	 	 
	 	(l) 	
      agreed, whether in writing or orally, to do any of the
      foregoing.

	4.18 	
      Absence of Certain Changes or Events. Except as
      publicly disclosed, there has not been:

	 	(a) 	
      a Pubco Material Adverse Effect; or

	 	 	 
	 	(b) 	
      any material change by Pubco in its accounting methods,
      principles or practices.

	4.19 	
      Subsidiaries. Except as publicly disclosed, Pubco
      does not have any subsidiaries or agreements of any nature to acquire any
      subsidiary or to acquire or lease any other business operations.

	 	 
	4.20 	
      Personal Property. Except as publicly disclosed,
      there are no material equipment, furniture, fixtures and other tangible
      personal property and assets owned or leased by Pubco.

	 	 
	4.21 	
      Intellectual Property Assets. Pubco owns or holds
      an interest (including by way of a licence) in all intellectual property
      assets necessary for the operation of the business of Pubco and its
      subsidiaries as it is currently conducted (collectively, the “Pubco
      Intellectual Property Assets”), including:

	 	(a) 	
      all functional business names, trading names, registered
      and unregistered trademarks, service marks, and applications
      (collectively, the “Pubco Marks”);

	 	 	 
	 	(b) 	
      all patents, patent applications, and inventions,
      methods, processes and discoveries that may be patentable (collectively,
      the “Pubco Patents”);

	 	 	 
	 	(c) 	
      all copyrights in both published works and unpublished
      works (collectively, the “Pubco Copyrights”); and

	 	 	 
	 	(d) 	
      all know-how, trade secrets, confidential information,
      customer lists, software, technical information, data, process technology,
      plans, drawings, and blue prints owned, used, or licensed by Pubco and its
      subsidiaries as licensee or licensor (collectively, the “Pubco Trade
      Secrets”).

- 21 - 

Execution version 

	4.22 	
      Employees and Consultants. Pubco has 7 employees
      and 3 consultants as at June 30, 2014. Except as disclosed by Pubco in
      writing, all employees and consultants of Pubco and its subsidiaries have
      been paid all salaries, wages, income and any other sum due and owing to
      them by Pubco or its subsidiaries, as at the end of the most recent
      completed pay period. Neither Pubco nor any of its subsidiaries is aware
      of any labor conflict with any employees that might reasonably be expected
      to have a Pubco Material Adverse Effect. To the best knowledge of Pubco,
      no employee of Pubco or any of its subsidiaries is in violation of any
      term of any employment contract, non-disclosure agreement, non-competition
      agreement or any other contract or agreement relating to the relationship
      of such employee with Pubco or its subsidiaries or any other nature of the
      business conducted or to be conducted by Pubco its subsidiaries.

	 	 
	4.23 	
      Material Contracts and Transactions. Other than as
      publicly disclosed, there are no material contracts, agreements, licenses,
      permits, arrangements, commitments, instruments, understandings or
      contracts, whether written or oral, express or implied, contingent, fixed
      or otherwise, to which Pubco is a party except as disclosed in writing to
      Priveco.

	 	 
	4.24 	
      No Brokers. Pubco has not incurred any obligation
      or liability to any party for any brokerage fees, agent’s commissions, or
      finder’s fees in connection with the Transaction contemplated by this
      Agreement.

	 	 
	4.25 	
      Completeness of Disclosure. No representation or
      warranty by Pubco in this Agreement nor any certificate, schedule,
      statement, document or instrument furnished or to be furnished to Priveco
      pursuant hereto contains or will contain any untrue statement of a
      material fact or omits or will omit to state a material fact required to
      be stated herein or therein or necessary to make any statement herein or
      therein not materially misleading. All information relating to Pubco or
      its assets or affairs which would be material to a buyer of Pubco Shares
      was disclosed to the Selling Shareholders. All information supplied by the
      Pubco or its agents, representatives and advisers to the Selling
      Shareholders or its agents, representatives and advisers is accurate,
      complete and not misleading.

	5. 	
      CLOSING CONDITIONS

	5.1 	
      Conditions Precedent to Closing by Pubco. The
      obligation of Pubco to consummate the Transaction is subject to the
      satisfaction or written waiver of the conditions set forth below by 31
      December 2014. The Closing of the Transaction contemplated by this
      Agreement will be deemed to mean a waiver of all conditions to Closing.
      These conditions precedent are for the benefit of Pubco and may be waived
      by Pubco in its sole discretion.

	 	(a) 	
      Representations and Warranties. The
      representations and warranties of Priveco and the Selling Shareholders set
      forth in this Agreement will be true, correct and complete in all respects
      as of the Closing Date, as though made on and as of the Closing Date and
      Priveco will have delivered to Pubco a certificate dated as of the Closing
      Date, to the effect that the representations and warranties made by
      Priveco in this Agreement are true and correct, subject only to possible
      additional disclosures made in writing, which Pubco will have found
      acceptable in its reasonable discretion.

- 22 - 

Execution version 

	 	(b) 	
      Performance. All of the covenants and obligations
      that Priveco and the Selling Shareholders are required to perform or to
      comply with pursuant to this Agreement at or prior to the Closing must
      have been performed and complied with in all material respects.

	 	 	 	 
	 	(c) 	
      Transaction Documents. This Agreement, the Priveco
      Documents, and all other documents necessary or reasonably required to
      consummate the Transaction, all in form and substance reasonably
      satisfactory to Pubco, will have been executed and delivered to
    Pubco.

	 	 	 	 
	 	(d) 	
      Certificate – Priveco. Pubco will have received a
      certificate from Priveco attaching:

	 	 	 	 
	 		(i) 	
      a copy of Priveco’s Certificate of Incorporation,
      Articles of Incorporation and all other incorporation documents, as
      amended through the Closing Date; and

	 	 	 	 
	 		(ii) 	
      copies of resolutions duly adopted by the board of
      directors of Priveco approving the execution and delivery of this
      Agreement and the consummation of the transactions contemplated
    herein.

	 	 	 	 
	 	(e) 	
      Legal Opinion – Priveco. Pubco will have received
      an opinion, dated as of the Closing Date, from counsel for Priveco, and
      such other local or special counsel as is appropriate, as to the
      existence, capacity and authority of Priveco, all of which opinion will be
      in the form and substance reasonably satisfactory to Pubco and its
      counsel.

	 	 	 	 
	 	(f) 	
      No Material Adverse Change. No Priveco Material
      Adverse Effect will have occurred since the date of this
  Agreement.

	 	 	 	 
	 	(g) 	
      No Action. No suit, action, or proceeding will be
      pending or threatened which would:

	 	 	 	 
	 		(i) 	
      prevent the consummation of any of the transactions
      contemplated by this Agreement; or

	 	 	 	 
	 		(ii) 	
      cause the Transaction to be rescinded following
      consummation.

	 	 	 	 
	 	(h) 	
      Outstanding Shares. Priveco will have issued and
      outstanding no more than the number of shares of Priveco Shares issued and
      outstanding on the Closing Date as is set out on Schedule 1.

	 	 	 	 
	 	(i) 	
      Due Diligence Generally. Pubco and its solicitors
      will be reasonably satisfied with their due diligence investigation of
      Priveco that is reasonable and customary in a transaction of a similar
      nature to that contemplated by the Transaction, including:

	 	 	 	 
	 		(i) 	
      materials, documents and information in the possession
      and control of Priveco and the Selling Shareholders which are reasonably
      germane to the Transaction;

	 	 	 	 
	 		(ii) 	
      the audited financial statements for Priveco for the
      fiscal year ended December 31, 2013 and auditor reviewed financial
      statements for the period ended on 31 August 2014, as described in section
      7.4;

- 23 - 

Execution version 

	 	(iii) 	
      a physical inspection of the assets of Priveco by Pubco
      or its representatives; and title to the material assets of
  Priveco.

	 	(j) 	
      Compliance with Securities Laws. Pubco will have
      received evidence satisfactory to Pubco that the Consideration Shares
      issuable in the Transaction will be issuable without registration pursuant
      to the Securities Act in reliance on an exemption from the registration
      requirements of the Securities Act provided by Regulation S and/or
      Regulation D.

	 	 	 
	 		
      In order to establish the availability of the safe harbor
      from the registration requirements of the Securities Act for the issuance
      of Consideration Shares to each Selling Shareholder or their nominees,
      Priveco will deliver to Pubco on Closing, the applicable Certificate duly
      executed by each Selling Shareholder.

	5.2 	
      Conditions Precedent to Closing by Priveco. The
      obligation of Priveco and the Selling Shareholders to consummate the
      Transaction is subject to the satisfaction or written waiver of the
      conditions set forth below by 31 December 2014, except for condition (j)
      below which must be satisfied by 15 November 2014. The Closing of the
      Transaction will be deemed to mean a waiver of all conditions to Closing.
      These conditions precedent are for the benefit of Priveco and the Selling
      Shareholders and may be waived by Priveco and the Selling Shareholders in
      their discretion.

	 	(a) 	
      Representations and Warranties. The
      representations and warranties of Pubco set forth in this Agreement will
      be true, correct and complete in all respects as of the Closing Date, as
      though made on and as of the Closing Date and Pubco will have delivered to
      Priveco a certificate dated the Closing Date, to the effect that the
      representations and warranties made by Pubco in this Agreement are true
      and correct.

	 	 	 	 
	 	(b) 	
      Performance. All of the covenants and obligations
      that Pubco is required to perform or to comply with pursuant to this
      Agreement at or prior to the Closing must have been performed and complied
      with in all material respects. Pubco must have delivered each of the
      documents required to be delivered by it pursuant to this
  Agreement.

	 	 	 	 
	 	(c) 	
      Transaction Documents. This Agreement, the Pubco
      Documents and all other documents necessary or reasonably required to
      consummate the Transaction, all in form and substance reasonably
      satisfactory to Priveco, will have been executed and delivered by
      Pubco.

	 	 	 	 
	 	(d) 	
      Secretary’s Certificate - Pubco. Priveco will have
      received a certificate from the Secretary of Pubco attaching:

	 	 	 	 
	 		(i) 	
      a copy of Pubco’s Articles of Incorporation and Bylaws,
      as amended through the Closing Date; and

	 	 	 	 
	 		(ii) 	
      copies of resolutions duly adopted by the board of
      directors of Pubco approving the execution and delivery of this Agreement
      and the consummation of the transactions contemplated
  herein.

- 24 - 

Execution version 

	 	(e) 	
      Legal Opinion – Pubco. Priveco will have received
      a legal opinion, dated as of the Closing Date, from counsel for Pubco, and
      such other local or special legal counsel as is appropriate, all of which
      opinion shall be in the form and substance reasonably satisfactory to
      Priveco and its counsel.

	 	 	 	 
	 	(f) 	
      Third Party Consents. Priveco will have received
      from Pubco duly executed copies of all third-party consents, permits,
      authorisations and approvals of any public, regulatory or governmental
      body or authority or person or entity contemplated by this Agreement, in
      the form and substance reasonably satisfactory to Priveco.

	 	 	 	 
	 	(g) 	
      No Material Adverse Change. No Pubco Material
      Adverse Effect will have occurred since the date of this
  Agreement.

	 	 	 	 
	 	(h) 	
      No Action. No suit, action, or proceeding will be
      pending or threatened before any governmental or regulatory authority
      wherein an unfavorable judgment, order, decree, stipulation, injunction or
      charge would:

	 	 	 	 
	 		(i) 	
      prevent the consummation of any of the transactions
      contemplated by this Agreement; or

	 	 	 	 
	 		(ii) 	
      cause the Transaction to be rescinded following
      consummation.

	 	 	 	 
	 	(i) 	
      Director Appointment. Pubco will have delivered at
      the Closing an appointment of representatives of the Selling Shareholders
      to fill in two positions on the board of Pubco and two positions on the
      board of Priveco (the "Priveco Directors") effective immediately
      after the Closing. Each such proposed representative shall be reasonably
      acceptable to Pubco.

	 	 	 	 
	 	(j) 	
      Improcells subsidy. Pubco shall have obtained the
      signed confirmation from DGO6 of the Walloon Public Service that the
      subsidy related to the Improcells project is granted to Orgenesis
    SPRL.

	6. 	
      ADDITIONAL COVENANTS OF THE
  PARTIES

	6.1 	
      Access and Investigation. Between the date of this
      Agreement and the Closing Date, Priveco, on the one hand, and Pubco, on
      the other hand, will, and will cause each of their respective
      representatives to:

	 	(a) 	
      afford the other and its representatives full and free
      access to its personnel, properties, assets, contracts, books and records,
      and other documents and data;

	 	 	 
	 	(b) 	
      furnish the other and its representatives with copies of
      all such contracts, books and records, and other existing documents and
      data as required by this Agreement and as the other may otherwise
      reasonably request; and

	 	 	 
	 	(c) 	
      furnish the other and its representatives with such
      additional financial, operating, and other data and information as the
      other may reasonably request.

- 25 - 

Execution version 

		
      All of such access, investigation and communication by a
      party and its representatives will be conducted during normal business
      hours and in a manner designed not to interfere unduly with the normal
      business operations of the other party. Each party will instruct its
      auditors to cooperate with the other party and its representatives in
      connection with such investigations.

	 	 
	6.2 	
      Confidentiality. All information regarding the
      business of Priveco including, without limitation, financial information
      that Priveco provides to Pubco during Pubco’s due diligence investigation
      of Priveco will be kept in strict confidence by Pubco and will not be used
      (except in connection with due diligence), dealt with, exploited or
      commercialized by Pubco or disclosed to any third party (other than
      Pubco’s professional accounting and legal advisors) without the prior
      written consent of Priveco. If the Transaction contemplated by this
      Agreement does not proceed for any reason, then upon receipt of a written
      request from Priveco, Pubco will immediately return to Priveco (or as
      directed by Priveco) any information received regarding Priveco’s
      business. Likewise, all information regarding the business of Pubco
      including, without limitation, financial information that Pubco provides
      to Priveco during its due diligence investigation of Pubco will be kept in
      strict confidence by Priveco and will not be used (except in connection
      with due diligence), dealt with, exploited or commercialized by Priveco or
      disclosed to any third party (other than Priveco’s professional accounting
      and legal advisors) without Pubco’s prior written consent. If the
      Transaction contemplated by this Agreement does not proceed for any
      reason, then upon receipt of a written request from Pubco, Priveco will
      immediately return to Pubco (or as directed by Pubco) any information
      received regarding Pubco’ s business.

	 	 
	6.3 	
      Notification. Between the date of this Agreement
      and the Closing Date, each of the parties to this Agreement will promptly
      notify the other parties in writing if it becomes aware of any fact or
      condition that causes or constitutes a material breach of any of its
      representations and warranties as of the date of this Agreement, if it
      becomes aware of the occurrence after the date of this Agreement of any
      fact or condition that would cause or constitute a material breach of any
      such representation or warranty had such representation or warranty been
      made as of the time of occurrence or discovery of such fact or condition.
      Should any such fact or condition require any change in the Schedules
      relating to such party, such party will promptly deliver to the other
      parties a supplement to the Schedules specifying such change. During the
      same period, each party will promptly notify the other parties of the
      occurrence of any material breach of any of its covenants in this
      Agreement or of the occurrence of any event that may make the satisfaction
      of such conditions impossible or unlikely.

	 	 
	6.4 	
      Conduct of Priveco and Pubco Business Prior to
      Closing. From the date of this Agreement to the Closing Date, and
      except to the extent that Pubco otherwise consents in writing, Priveco
      will operate its business substantially as presently operated and only in
      the ordinary course and in compliance with all applicable laws, and use
      its best efforts to preserve intact its good reputation and present
      business organization and to preserve its relationships with persons
      having business dealings with it. Likewise, from the date of this
      Agreement to the Closing Date, and except to the extent that Priveco
      otherwise consents in writing, Pubco will operate its business
      substantially as presently operated and only in the ordinary course and in
      compliance with all applicable laws, and use its best efforts to preserve
      intact its good reputation and present business organization and to
      preserve its relationships with persons having business dealings with
      it.

- 26 - 

Execution version 

	6.5 	
      Certain Acts Prohibited – Priveco. Except as
      expressly contemplated by this Agreement or for purposes in furtherance of
      this Agreement, between the date of this Agreement and the Closing Date,
      Priveco will not, without the prior written consent of
  Pubco:

	 	(a) 	
      amend its Articles of Association;

	 	 	 
	 	(b) 	
      incur any liability or obligation other than in the
      ordinary course of business or encumber or permit the encumbrance of any
      properties or assets of Priveco except in the ordinary course of
      business;

	 	 	 
	 	(c) 	
      dispose of or contract to dispose of any Priveco property
      or assets, including the Intellectual Property Assets, except in the
      ordinary course of business consistent with past practice;

	 	 	 
	 	(d) 	
      issue, deliver, sell, pledge or otherwise encumber or
      subject to any lien any shares of the Priveco Shares, or any rights,
      warrants or options to acquire, any such shares, voting securities or
      convertible securities;

	 	 	 
	 	(e) 	
      declare, set aside or pay any dividends on, or make any
      other distributions in respect of the Priveco Shares,

	 	 	 
	 	(f) 	
      split, combine or reclassify any Priveco Shares or issue
      or authorize the issuance of any other securities in respect of, in lieu
      of, in addition to or in substitution for Priveco Shares; or

	 	 	 
	 	(g) 	
      materially increase benefits or compensation expenses of
      Priveco, other than as contemplated by the terms of any employment
      agreement in existence on the date of this Agreement, increase the cash
      compensation of any director, executive officer or other key employee or
      pay any benefit or amount not required by a plan or arrangement as in
      effect on the date of this Agreement to any such
person.

	6.6 	
      Certain Acts Prohibited - Pubco. Except as
      expressly contemplated by this Agreement, between the date of this
      Agreement and the Closing Date, Pubco will not, without the prior written
      consent of Priveco:

	 	(a) 	
      amend its Certificate of Incorporation, Articles of
      Incorporation or other incorporation documents;

	 	 	 
	 	(b) 	
      incur any liability or obligation or encumber or permit
      the encumbrance of any properties or assets of Pubco except in the
      ordinary course of business consistent with past practice;

	 	 	 
	 	(c) 	
      dispose of or contract to dispose of any Pubco property
      or assets, including the Pubco Intellectual Property Assets, except in the
      ordinary course of business consistent with past practice;

	 	 	 
	 	(d) 	
      declare, set aside or pay any dividends on, or make any
      other distributions in respect of the Pubco Common Stock;
  or

- 27 - 

Execution version 

	 	(e) 	
      increase benefits or compensation expenses of Pubco,
      increase the cash compensation of any director, executive officer or other
      key employee or pay any benefit or amount to any such person, except in
      the ordinary course of business.

	6.7 	
      Public Announcements. Pubco and Priveco each agree
      that they will not release or issue any reports or statements or make any
      public announcements relating to this Agreement or the Transaction
      contemplated herein without the prior written consent of the other party,
      except as may be required upon written advice of counsel to comply with
      applicable laws or regulatory requirements after consulting with the other
      party hereto and seeking their reasonable consent to such
    announcement.

	 	 
	6.8 	
      Employment Agreements. Between the date of this
      Agreement and the Closing Date, Priveco will have made necessary
      arrangements to employ such of the hourly and salaried employees of
      Priveco as are reasonably necessary to operate such business substantially
      as presently operated. Upon Pubco's request, Priveco agrees to provide
      copies of all such agreements and arrangements that evidence such
      employment at or prior to Closing.

	7. 	
      CLOSING

	7.1 	
      Closing. The Closing shall take place on the
      Closing Date at the offices of the lawyers for Pubco or at such other
      location as agreed to by the parties. Notwithstanding the location of the
      Closing, each party agrees that the Closing may be completed by the
      exchange of undertakings between the respective legal counsel for Priveco
      and Pubco, provided such undertakings are satisfactory to each party’s
      respective legal counsel.

	 	 
	7.2 	
      Closing Deliveries of Priveco and the Selling
      Shareholders. At Closing, Priveco and the Selling Shareholders will
      deliver or cause to be delivered the following, fully executed and in the
      form and substance reasonably satisfactory to
Pubco:

	 	(a) 	
      copies of all resolutions and/or consent actions adopted
      by or on behalf of the board of directors of Priveco evidencing approval
      of this Agreement and the Transaction;

	 	 	 
	 	(b) 	
      if any of the Selling Shareholders appoint any person, by
      power of attorney or equivalent, to execute this Agreement or any other
      agreement, document, instrument or certificate contemplated by this
      agreement, on behalf of the Selling Shareholder, a valid and binding power
      of attorney or equivalent from such Selling Shareholder;

	 	 	 
	 	(c) 	
      excerpts of Priveco's share registers, filled in as
      required by this Agreement;

	 	 	 
	 		
      and

	 	 	 
	 	(d) 	
      the Priveco Documents and any other necessary documents,
      each duly executed by Priveco, as required to give effect to the
      Transaction.

	7.3 	
      Closing Deliveries of Pubco. At Closing, Pubco
      will deliver or cause to be delivered the following, fully executed and in
      the form and substance reasonably satisfactory to
  Priveco:

	 	(a) 	
      copies of all resolutions and/or consent actions adopted
      by or on behalf of the board of directors of Pubco evidencing approval of
      this Agreement and the Transaction;

- 28 - 

Execution version 

	 	(b) 	
      all certificates and other documents required by this
      Agreement; a certificate of an officer of Pubco, dated as of Closing,
      certifying that: each covenant and obligation of Pubco has been complied
      with; and

	 	 	 
	 	(c) 	
      each representation, warranty and covenant of Pubco is
      true and correct at the Closing as if made on and as of the Closing;
      and

	 	 	 
	 	(d) 	
      the Pubco Documents and any other necessary documents,
      each duly executed by Pubco, as required to give effect to the
      Transaction.

	7.4 	
      Delivery of Financial Statements. Prior to the
      Closing Date, Priveco will have delivered to Pubco the Priveco Financial
      Statements, which financial statements will include audited financial
      statements for the most recently completed fiscal year end, prepared in
      accordance with GAAP and audited by an independent auditor registered with
      the Public Company Accounting Oversight Board in the United States, and
      auditor reviewed financial statements to 31 August 2014. The parties
      acknowledge that within 75 days of Closing, Pubco is required to file with
      the SEC the Priveco Financial Statements, together with a pro forma of
      Pubco financial statements as at a recent date, together with substantial
      information on the operations, business, management, industry and risks of
      Priveco. The Selling Shareholders will fully cooperate in this effort to
      ensure timely filing.

	 	 
	7.5 	
      Additional Closing
Actions.

	 	(a) 	
      At Closing, the Selling Shareholders shall enter into the
      Escrow Agreement and Pubco will deliver or cause to be delivered into
      escrow with the Escrow Agent the share certificates representing the
      Consideration Shares.

	 	 	 
	 	(b) 	
      At Closing, the articles of association of Priveco shall
      be amended so as to provide that the following decisions shall be subject
      to majority approval of the Priveco Board of Directors, which must include
      the approval of the Priveco Directors for a period ending on 31 March 2015
      for the decisions sub (i) to (xvii) and for 24 months after Closing for
      the decision sub (v), (ix) and (xi):

	 	(i) 	
      changes to the articles of Priveco;

	 	 	 
	 	(ii) 	
      any change in the authorized capital of
Priveco;

	 	 	 
	 	(iii) 	
      approval of Priveco's annual business plan;

	 	 	 
	 	(iv) 	
      the issuance of any additional shares of
  Priveco;

	 	 	 
	 	(v) 	
      the entering into by Priveco of an amalgamation, merger
      or consolidation with any other person;

	 	 	 
	 	(vi) 	
      any borrowing of money or assumption of indebtedness by
      Priveco which is not provided for in Priveco’s business plan or any
      request to postpone any scheduled repayment of outstanding indebtedness of
      Priveco;

- 29 - 

	 	(vii) 	
      the granting of any security or creation of any
      encumbrances on the assets of Priveco;

	 	 	 
	 	(viii) 	
      any loans made by Priveco to third parties, or guarantees
      by Priveco of third party indebtedness, other than in accordance with
      Priveco's respective business plan;

	 	 	 
	 	(ix) 	
      carrying on any business by Priveco other than the
      existing business or any change in any material aspect of Priveco's
      business, including a change of the location where the business is carried
      out;

	 	 	 
	 	(x) 	
      the sale, lease, exchange or disposition of any
      intellectual property assets or of all or substantially all of the other
      property or assets of Priveco or the acquisition of assets outside the
      ordinary course of business by Priveco;

	 	 	 
	 	(xi) 	
      the taking of any steps to wind-up, terminate the
      corporate existence or undertake a plan of arrangement in respect of
      Priveco;

	 	 	 
	 	(xii) 	
      the declaration or payment by Priveco of any
    dividend;

	 	 	 
	 	(xiii) 	
      any contractual arrangement between a shareholder (or any
      associated, related or affiliated person thereto) and Priveco, including
      such contracts (and any change in the terms of such contracts, including
      the level of remuneration), or benefits which relate to the employment of
      any person by Priveco;

	 	 	 
	 	(xiv) 	
      the entering into by Priveco of a partnership or of any
      arrangement for the sharing of profits, union of interests, joint venture
      or reciprocal concession with any person;

	 	 	 
	 	(xv) 	
      the giving of approval for any transfer of shares of
      Priveco or any issuance of Priveco shares to a person;

	 	 	 
	 	(xvi) 	
      the delegation by the board of directors of Priveco of
      any of its powers; and

	 	 	 
	 	(xvii) 	
      any change in the fiscal year end of
  Priveco.

	 	(c) 	
      At Closing, the bylaws of Pubco shall be amended so as to
      provide that the following decisions shall be subject to a majority
      approval of the Pubco Board of Directors which must include the Priveco
      Directors for a period ending at the earlier of (i) expiry of the Lock-up
      (ii) the date the Selling Shareholders hold less than 20% of the then
      outstanding Pubco Common Stock or (iii) the date the Unwinding is
      exercised:

	 	(i) 	
      approval of Pubco's annual business plan;

	 	 	 
	 	(ii) 	
      the issuance of any additional shares of Pubco;

	 	 	 
	 	(iii) 	
      the entering into by Pubco of an amalgamation, merger or
      consolidation with any other person;

- 30 - 

Execution version 

	 	(iv) 	
      any borrowing of money or assumption of indebtedness by
      Pubco which is not provided for in Pubco’s business plan or any request to
      postpone any scheduled repayment of outstanding indebtedness of Pubco,
      both other than in the ordinary course of business;

	 	 	 
	 	(v) 	
      the granting of any security or creation of any
      encumbrances on the assets of Pubco other than in the ordinary course of
      business;

	 	 	 
	 	(vi) 	
      any loans made by Pubco to third parties, or guarantees
      by Pubco of third party indebtedness, other than in accordance with
      Pubco's respective business plan and other than in the ordinary course of
      business;

	 	 	 
	 	(vii) 	
      carrying on any business by Pubco other than the existing
      business or any material change of Pubco's business;

	 	 	 
	 	(viii) 	
      the sale, lease, exchange or disposition of any
      intellectual property assets or of all or substantially all of the other
      property or assets of Pubco or the acquisition of assets outside the
      ordinary course of business by Pubco;

	 	 	 
	 	(ix) 	
      the taking of any steps to wind-up, terminate the
      corporate existence or undertake a plan of arrangement in respect of
      Pubco;

	 	 	 
	 	(x) 	
      the entering into by Pubco of a partnership or of any
      arrangement for the sharing of profits, union of interests, joint venture
      or reciprocal concession with any person;

	 	 	 
	 	(xi) 	
      the giving of approval for any transfer of shares of
      Pubco or any issuance of Pubco shares to a
person.

	8. 	
      TERMINATION

	8.1 	
      Termination. This Agreement may be terminated at
      any time prior to the Closing Date contemplated hereby
  by:

	 	(a) 	
      mutual agreement of Pubco and Priveco;

	 	 	 
	 	(b) 	
      Pubco, if there has been a material breach by Priveco or
      any of the Selling Shareholders of any material representation, warranty,
      covenant or agreement set forth in this Agreement on the part of Priveco
      or the Selling Shareholders that is not cured, to the reasonable
      satisfaction of Pubco, within ten business days after notice of such
      breach is given by Pubco (except that no cure period will be provided for
      a breach by Priveco or the Selling Shareholders that by its nature cannot
      be cured);

	 	 	 
	 	(c) 	
      Priveco, if there has been a material breach by Pubco of
      any material representation, warranty, covenant or agreement set forth in
      this Agreement on the part of Pubco that is not cured by the breaching
      party, to the reasonable satisfaction of Priveco, within ten business days
      after notice of such breach is given by Priveco (except that no cure
      period will be provided for a breach by Pubco that by its nature cannot be
      cured);

- 31 - 

Execution version 

	 	(d) 	
      Pubco or Priveco, if the Transaction contemplated by this
      Agreement has not been consummated prior to December 31, 2014, without
      violation by any party of any obligation under this Agreement and unless
      the parties hereto agree to extend such date in writing; or

	 	 	 
	 	(e) 	
      Pubco or Priveco if any permanent injunction or other
      order of a governmental entity of competent authority preventing the
      consummation of the Transaction contemplated by this Agreement has become
      final and non-appealable.

	8.2 	
      Effect of Termination. In the event of the
      termination of this Agreement as provided in this Section, this Agreement
      will be of no further force or effect, provided, however, that no
      termination of this Agreement will relieve any party of liability for any
      breaches of this Agreement that are based on a wrongful refusal or failure
      to perform any obligations.

	9. 	
      INDEMNIFICATION, REMEDIES,
  SURVIVAL

	9.1 	
      Certain Definitions. For the purposes of this
      Article 9, the terms “Loss” and “Losses” mean any and all
      demands, claims, actions or causes of action, assessments, losses,
      damages, Liabilities, costs, and expenses, including without limitation,
      interest, penalties, fines and reasonable attorneys, accountants and other
      professional fees and expenses, but excluding any indirect, consequential
      or punitive damages suffered by Pubco or Priveco, including damages for
      lost profits or lost business opportunities.

	 	 
	9.2 	
      Agreement of Priveco to Indemnify. Priveco will
      indemnify, defend, and hold harmless, to the full extent of the law, Pubco
      and its shareholders from, against, and in respect of any and all Losses
      asserted against, relating to, imposed upon, or incurred by Pubco and its
      shareholders by reason of, resulting from, based upon or arising out
      of:

	 	(a) 	
      the breach by Priveco of any representation or warranty
      of Priveco contained in or made pursuant to this Agreement, any Priveco
      Document or any certificate or other instrument delivered pursuant to this
      Agreement; or

	 	 	 
	 	(b) 	
      the breach or partial breach by Priveco of any covenant
      or agreement of Priveco made in or pursuant to this Agreement, any Priveco
      Document or any certificate or other instrument delivered pursuant to this
      Agreement.

	9.3 	
      Agreement of Pubco to Indemnify. Pubco will
      indemnify, defend, and hold harmless, to the full extent of the law,
      Priveco and the Selling Shareholders at any time from, against, for, and
      in respect of any and all Losses asserted against, relating to, imposed
      upon, or incurred by Priveco and the Selling Shareholders at any time by
      reason of, resulting from, based upon or arising out
of:

	 	(a) 	
      the breach by Pubco of any representation or warranty of
      Pubco contained in or made pursuant to this Agreement, any Pubco Document
      or any certificate or other instrument delivered pursuant to this
      Agreement; or

	 	 	 
	 	(b) 	
      the breach or partial breach by Pubco of any covenant or
      agreement of Pubco made in or pursuant to this Agreement, any Pubco
      Document or any certificate or other instrument delivered pursuant to this
      Agreement.

- 32 - 

	10. 	
      POST CLOSING
AGREEMENTS

	10.1 	
      Pubco will keep Priveco as a separate subsidiary for a
      period ending at least 2 years from the Closing Date.

	 	 
	10.2 	
      Pubco agrees that it will apply for a listing of its
      shares on NASDAQ or any other national exchange in the United States of
      America which provides at least the same level of liquidity (the
      “Uplisting”) within 12 months of Closing Date and that it will use
      its reasonable best efforts to achieve such a listing within fourteen (14)
      months of Closing Date. As from Closing a working group composed of three
      (3) representatives selected by the Selling Shareholders and three (3)
      representatives from Pubco, among which the CEO of Pubco, shall supervise
      the progress made towards the application for and subsequent Uplisting of
      Pubco and shall act in an advisory capacity towards the management of
      Pubco. The working group shall hold teleconferences every fortnight. On
      the occasion of these teleconferences, the CEO of Pubco shall update the
      other members of the working group of the status of the application for
      and subsequent listing of Pubco and shall inform them of any material
      obstacles, constraints, actual or potential delays encountered.

	 	 
	10.3 	
      Pubco agrees that it will raise a minimum of $10,000,000
      in an equity or debt financing (the “Post Closing Financing”)
      within 8 months of the Closing Date.

	 	 
	10.4 	
      The parties agree that on the date immediately after the
      Post Closing Financing, Pubco will be valued for purposes of the Unwinding
      trigger described below. The valuation of Pubco (the “Valuation”)
      is required to be a minimum of $45,000,000 (the “Valuation
      Threshold”). The Valuation is deemed to meet the Valuation Threshold
      if the number of shares of common stock of Pubco outstanding multiplied by
      the average of all closing trading prices of Pubco’s shares on its
      principal trading market over a period of 30 days following the Post
      Closing Financing exceeds the Valuation Threshold.

	 	 
	10.5 	
      In the event that Pubco has not achieved the Post Closing
      Financing and a Valuation which meets the Valuation Threshold within eight
      (8) months of the Closing Date, then the Selling Shareholders may by
      notice (the “Unwind Notice”) to Pubco unwind the Transaction by
      delivering to Pubco all of the Consideration Shares plus any amount that
      Pubco has advanced or invested in Priveco, in dollars, as per the auditors
      of Pubco (the “Investment”). The Unwind Notice must be delivered
      within 10 days of the said eight month anniversary of the Closing Date and
      the Consideration Shares and the Investment must be delivered within 30
      days of such anniversary, and Pubco will deliver to the Selling
      Shareholders all Priveco Shares (the
“Unwinding”).

	11. 	
      CONVERTIBLE BONDS

	11.1 	
      In case of conversion of the Convertible Bonds upon
      Uplisting within 14 months of the Closing Date, the Selling Shareholders
      (other than the former Bondholders) shall (and shall ensure that the
      Bondholders shall):

	 	(a) 	
      exchange the Conversion Shares for a number of
      Consideration Shares corresponding to the percentage set out opposite each
      such Bondholder’s name in Schedule 1, based on the Consideration Share
      pricing set forth in section 2.2 above; and

- 33 - 

Execution version 

	 	(b) 	
      shall transfer the Conversion Shares to Pubco for no
      additional consideration and the total number of Consideration Shares
      shall be deemed to be the consideration for the new total number of
      Priveco Shares, including the Conversion
Shares.

	11.2 	
      In case the Bondholders elect not to exchange the
      Convertible Bonds for MasTHercell Common Stock and shall therefore lose
      their right to convert them, or in case the Bondholders are not allowed to
      convert the Convertible Bonds in the absence of Uplisting within 14 months
      of the Closing Date and the Convertible Bonds remain a liability of
      MasTHerCell, then the Consideration payable in Consideration Shares will
      be reduced by the amount that was due at Closing to those Bondholders who
      do not exchange their Convertible Bonds. To that effect, the number of
      Consideration Shares to be released back to Pubco shall be determined by
      dividing the subscription amount of the outstanding Convertible Bonds plus
      interest owed thereunder (converted into USD according to the currency
      exchange rate applicable on the day of conversion) by the Consideration
      and by applying the resulting quotient to the actual total number of
      Consideration Shares.

	 	 
	11.3 	
      In case of release for cancellation of Consideration
      Shares under section 11.2, each Selling Shareholder, other than the
      Bondholders, will give up for cancellation a part of its Consideration
      Shares that will be proportionate to such Selling Shareholders' share in
      the total number of Consideration Shares issued at Closing (see Schedule
      I, A, column III).

	 	 
	11.4 	
      The board of Pubco shall notify the Escrow Agent in
      writing of the Consideration Shares to be released to the Bondholders
      pursuant to section 11.1 above or, as the case may be, cancelled pursuant
      to sections 11.2 and 11.3 above. Such notification shall comply with the
      requirements as to form and content described in the Escrow Agreement
      enclosed as Schedule 9.

	12. 	
      MISCELLANEOUS
PROVISIONS

	12.1 	
      Effectiveness of Representations; Survival. Each
      party is entitled to rely on the representations, warranties and
      agreements of each of the other parties and all such representation,
      warranties and agreement will be effective regardless of any investigation
      that any party has undertaken or failed to undertake. Unless otherwise
      stated in this Agreement, and except for instances of fraud, the
      representations, warranties and agreements will survive the Closing Date
      and continue in full force and effect until one (1) year after the Closing
      Date.

	 	 
	12.2 	
      Further Assurances. Each of the parties hereto
      will co-operate with the others and execute and deliver to the other
      parties hereto such other instruments and documents and take such other
      actions as may be reasonably requested from time to time by any other
      party hereto as necessary to carry out, evidence, and confirm the intended
      purposes of this Agreement.

	 	 
	12.3 	
      Amendment. This Agreement may not be amended
      except by an instrument in writing signed by each of the
parties.

	 	 
	12.4 	
      Expenses. Pubco will bear all costs incurred in
      connection with the preparation, execution and performance of this
      Agreement and the Transaction contemplated hereby, including all fees and
      expenses of agents, representatives and accountants; provided that Pubco
      and Priveco will bear its respective legal costs incurred in connection
      with the preparation, execution and performance of this Agreement and the
      Transaction contemplated hereby.

- 34 - 

Execution version 

	12.5 	
      Entire Agreement. This Agreement, the schedules
      attached hereto and the other documents in connection with this
      transaction contain the entire agreement between the parties with respect
      to the subject matter hereof and supersede all prior arrangements and
      understandings, both written and oral, expressed or implied, with respect
      thereto. Any preceding correspondence or offers are expressly superseded
      and terminated by this Agreement.

	 	 
	12.6 	
      Notices. All notices and other communications
      required or permitted under to this Agreement must be in writing and will
      be deemed given if sent by personal delivery, faxed with electronic
      confirmation of delivery, internationally-recognized express courier or
      registered or certified mail (return receipt requested), postage prepaid,
      to the parties at the following addresses (or at such other address for a
      party as will be specified by like notice):

	 	(a) 	
      If to Priveco :

	 	MasTherCell SA or Cell Therapy Holdings
      SA 
	 	6041 Gosselies, rue Auguste Piccard 48, 
	 	Belgium 	  
	 	  	  
	 	Attention: 	Hugues Bultot, CEO 
	 	Email: 	hugues.bultot@masthercell.com

	 	(b) 	
      If to any of the Selling
Shareholders:

to that Selling Shareholder's address
as indicated in Schedule 1. 

With a copy which shall not constitute
notice to: 
Bird & Bird LLP
Avenue Louise 235, b.1 
1050 Brussels

Belgium 
Attention: Paul Hermant 

Email: paul.hermant@twobirds.com 

	 	(c) 	
      If to Pubco

	 	Orgenesis Inc. 
	 	21 Sparrow Circle 
	 	White Plains NY 10605 
	 	United States of America 
	 	  	  
	 	Attention: 	Vered Caplan, President and CEO 
	 	Email: 	veredc@orgenesis.com 

All such notices and other
communications will be deemed to have been received: in the case of personal
delivery, on the date of such delivery via electronic transmission, and in the
case of delivery by an internationally-recognized courier, on the day of
delivery or, if not a business day, on the next business day. 

- 35 - 

Execution version 

	12.7 	
      Headings. The headings contained in this Agreement
      are for convenience purposes only and will not affect in any way the
      meaning or interpretation of this Agreement.

	 	 
	12.8 	
      Benefits. This Agreement is and will only be
      construed as for the benefit of or enforceable by those persons party to
      this Agreement. Pubco will hold Priveco and the Selling Shareholders
      harmless for any damages, loss or other consequence resulting from any
      third party action against any of Priveco or the Selling Shareholders on
      the basis of information provided, or representations and warranties made,
      or actions to be taken to or for the benefit of Pubco under this
      Agreement, including by referring to the existence or content of this
      Agreement in any document made public or available to any third
    party.

	 	 
	12.9 	
      Assignment. This Agreement may not be assigned
      (except by operation of law) by any party without the consent of the other
      parties.

	 	 
	12.10 	
      Governing Law. This Agreement will be governed by
      and construed in accordance with the laws of the State of Nevada
      applicable to contracts made and to be performed therein.

	 	 
	12.11 	
      Construction. The language used in this Agreement
      will be deemed to be the language chosen by the parties to express their
      mutual intent, and no rule of strict construction will be applied against
      any party.

	 	 
	12.12 	
      Gender. All references to any party will be read
      with such changes in number and gender as the context or reference
      requires.

	 	 
	12.13 	
      Business Days. If the last or appointed day for
      the taking of any action required or the expiration of any rights granted
      herein shall be a Saturday, Sunday or a legal holiday in the Kingdom of
      Belgium, then such action may be taken or right may be exercised on the
      next succeeding day which is not a Saturday, Sunday or such a legal
      holiday.

	 	 
	12.14 	
      Counterparts. This Agreement may be executed in
      one or more counterparts, all of which will be considered one and the same
      agreement and will become effective when one or more counterparts have
      been signed by each of the parties and delivered to the other parties, it
      being understood that all parties need not sign the same
    counterpart.

	 	 
	12.15 	
      Execution. This Agreement may be executed by
      delivery of executed signature pages by electronic transmission and such
      execution and delivery will be effective for all purposes.

	 	 
	12.16 	
      Schedules and Exhibits. The schedules and exhibits
      are attached to this Agreement and incorporated
herein.

- 36 - 

Execution version 

IN WITNESS WHEREOF the parties hereto have executed this
Agreement as of the day and year first above written. 

MASTHERCELL SA 

	Per: 	/s/ Hugues Bultot 
	  	Authorized Signatory 
	  	Name: Hugues Bultot 
	  	Title: CEO 

CELL THERAPY HOLDING SA 

	Per: 	/s/ Hugues Bultot 
	  	Authorized Signatory 
	  	Name: Hugues Bultot 
	  	Title: CEO 

ORGENESIS, INC 

	Per 	/s/ Vered Caplan 
	  	Authorized Signatory 
	  	Name: Vered Caplan 
	  	Title: President 

UNIVERSITE LIBRE DE BRUXELLES 

	Per             
      ____________________	Per             
      ____________________ 
	               
         Authorized Signatory 	                   Authorized
      Signatory 
	               
         Name: 	                   Name:
    
	               
         Title: 	                   Title:
    

- 37 - 

Execution version 

HUGUES BULTOT 

/s/ Hugues Bultot 

JOSÉ CASTILLO FERNANDEZ 

/s/ José Castillo Fernandez 

 

JPP CONSULTING SPRL 

	Per             
      ____________________
	               
         Authorized Signatory 
	               
         Name: 
	               
         Title: 

THEODORUS SCA 

	Per             
      ____________________
	               
         Authorized Signatory 
	               
         Name: 
	               
         Title: 

THEODORUS II SA 

	Per              ____________________
	               
         Authorized Signatory 
	               
         Name: 
	               
         Title: 

Execution version 

 

GABRIEL INVESTMENTS SPRL 

	Per             
      ____________________
	               
         Authorized Signatory 
	               
         Name: 
	               
         Title: 

AUXILIASTRA SPRL 

	Per             
      ____________________
	               
         Authorized Signatory 
	               
         Name: 
	               
         Title: 

GUILLAUME DE VIRON 

/s/ Guillaume de Viron 

 

ERIC MATHIEU 

/s/ Eric Mathieu 

 

4FORCELLS SPRL 

	Per             
      ____________________
	               
         Authorized Signatory 
	               
         Name: 
	               
         Title: 

- 39 - 

Execution version 

SCHEDULE 1 

TO THE SHARE EXCHANGE AGREEMENT AMONG ORGENESIS 
INC.,
MASTHERCELL SA, CELL THERAPY HOLDING SA AND THE SELLINGSHAREHOLDERS AS 
SET
OUT IN THE 
SHARE EXCHANGE AGREEMENT 

SELLING SHAREHOLDERS 

A.     
Shareholders of Priveco at Closing

	 MASTHERCELL SA SHAREHOLDERS 
  
	I. Name & address/registered office
    	II. Masthercell SA Common 	III. % in Priveco before 	IV. % in Priveco after 
	Shareholders 	Stock 	conversion of the Convertible 	conversion of the Convertible 
	  	  	Bonds 	Bonds 
	  	  	(% of Consideration Shares at 	(% of the total number of 
	  	  	Closing) 	Consideration Shares after 
	  	  	  	conversion of the Convertible 
	  	  	  	Bonds) 
	
    CELL THERAPY HOLDING SA 
	  	  	  
	
    Rue Auguste Piccard 48 
	  	  	  
	
    6041 Gosselies 
	  	  	  
	
    Belgium 
	1,200 	50% 	40.3452% 
	
      
	  	  	  
	
    Register of legal entities (district of 
	  	  	  
	
    Charleroi) number 0840.625.014 
	  	  	  
	
    UNIVERSITE LIBRE DE 
	  	  	  
	
    BRUXELLES 
	  	  	  
	
    Avenue Franklin D. Roosevelt, 50 
	750 	31.2500% 	25.2157% 
	
    1050 Brussels 
	  	  	  
	
    Belgium 
	  	  	  

- 40 - 

Execution version 

	 MASTHERCELL SA SHAREHOLDERS 
  
	I. Name & address/registered office
    	II. Masthercell SA Common 	III. % in Priveco before 	IV. % in Priveco after 
	Shareholders 	Stock 	conversion of the Convertible 	conversion of the Convertible 
	  	  	Bonds 	Bonds 
	  	  	(% of Consideration Shares at 	(% of the total number of 
	  	  	Closing) 	Consideration Shares after 
	  	  	  	conversion of the Convertible 
	  	  	  	Bonds) 
	
    Hugues BULTOT 
	  	  	  
	
    Avenue Victor Jacobs, 78, 
	  	  	  
	
    1040 Brussels 
	108 	4.50000% 	3.6311% 
	
    Belgium 
	  	  	  
	
    José CASTILLO FERNANDEZ, 
	  	  	  
	
    Rue de la Buanderie, 188/0007 boîte 3.1 
	  	  	  
	
    1080 Brussels 
	108 	4.5000% 	3.6311% 
	
    Belgium 
	  	  	  
	
    JPP CONSULTING SPRL 
	  	  	  
	
    Chemin du Gros Tienne, 61, 
	  	  	  
	
    1380 Lasne 
	  	  	  
	
    Belgium 
	100 	4.1667% 	3.3621% 
	
      
	  	  	  
	
    Register of legal entities (district of 
	  	  	  
	
    Nivelles) number 0829.890.923 
	  	  	  
	
    Eric MATHIEU 
	  	  	  
	
    Rue d'En haut 46 
	  	  	  
	
    5530 Dorinne 
	15 	0.6250% 	0.5043% 
	
    Belgium 
	  	  	  
	
    Guillaume DE VIRON 
	  	  	  
	
    Chemin du Bois de Villers 8b 
	15 	0.6250% 	0.5043% 
	
    1325 Corroy-le-Grand 
	  	  	  
	
    Belgium 
	  	  	  

- 41 - 

Execution version 

	 MASTHERCELL SA SHAREHOLDERS 
  
	I. Name & address/registered office
    	II. Masthercell SA Common 	III. % in Priveco before 	IV. % in Priveco after 
	Shareholders 	Stock 	conversion of the Convertible 	conversion of the Convertible 
	  	  	Bonds 	Bonds 
	  	  	(% of Consideration Shares at 	(% of the total number of 
	  	  	Closing) 	Consideration Shares after 
	  	  	  	conversion of the Convertible 
	  	  	  	Bonds) 
	
    GABRIEL INVESTMENTS SPRL 
	  	  	  
	
    Rue des Combattants 127 
	  	  	  
	
    1310 La Hulpe 
	  	  	  
	
    Belgium 
	15 	0.6250% 	0.5043% 
	
      
	  	  	  
	
    Register of legal entities (district of 
	  	  	  
	
    Nivelles) number 0833.996.694 
	  	  	  
	
    AUXILIASTRA SPRL 
	  	  	  
	
    Avenue Professeur Henrijean, 4 
	  	  	  
	
    4900 Spa 
	  	  	  
	
    Belgium 
	15 	0.6250% 	0.5043% 
	
      
	  	  	  
	
    Register of legal entities (district of 
	  	  	  
	
    Verviers) number 0829.890.923 
	  	  	  
	
    THEODORUS SCA 
	  	  	  
	
    Avenue Joseph Wybran 40 
	  	  	  
	
    1070 Anderlecht 
	  	  	  
	
    Belgium 
	37 	1.5417% 	1.2440% 
	
      
	  	  	  
	
    Register of legal entities (district of 
	  	  	  
	
    Brussels) number 0859.775.138 
	  	  	  

- 42 - 

Execution version 

	 MASTHERCELL SA SHAREHOLDERS 
  
	I. Name & address/registered office
    	II. Masthercell SA Common 	III. % in Priveco before 	IV. % in Priveco after 
	Shareholders 	Stock 	conversion of the Convertible 	conversion of the Convertible 
	  	  	Bonds 	Bonds 
	  	  	(% of Consideration Shares at 	(% of the total number of 
	  	  	Closing) 	Consideration Shares after 
	  	  	  	conversion of the Convertible 
	  	  	  	Bonds) 
	
    THEODORUS II SA 
	  	  	  
	
    Avenue Joseph Wybran 40 
	  	  	  
	
    1070 Anderlecht 
	  	  	  
	
    Belgium 
	37 	1.5417% 	1.2440% 
	
      
	  	  	  
	
    Register of legal entities (district of 
	  	  	  
	
    Brussels) number 0879.436.147 
	  	  	  
	
    TOTAL 
	  	  	  
	  	2,400 	  	  

- 43 - 

Execution version 

	 CELL THERAPY HOLDING SA
      SHAREHOLDERS  
	I. Name & address/registered office 	II. CTH Common Stock 	III. % in Priveco before 	IV. % in Priveco after 
	  	(shares and profit shares) 	conversion of the Convertible 	conversion of the Convertible 
	  	  	Bonds 	Bonds 
	  	  	(% of Consideration Shares at 	(% of the total number of 
	  	  	Closing) 	Consideration Shares after 
	  	  	  	conversion of the Convertible 
	  	  	  	Bonds) 
	
    THEODORUS SCA 
	  	  	  
	
    Avenue Joseph Wybran 40 
	300 shares 	7.4111% 	5.9800% 
	
    1070 Anderlecht 
	  	  	  
	
    Belgium 
	  	  	  
	
     
    
	  	  	  
	
    Register of legal entities (district of 
	200 profit shares 	4.9407% 	3.9867% 
	
    Brussels) number 0859.775.138 
	  	  	  
	
    THEODORUS II SA 
	  	  	  
	
    Avenue Joseph Wybran 40 
	300 	7.4111% 	5.9800% 
	
    1070 Anderlecht 
	  	  	  
	
    Belgium 
	  	  	  
	
     
    
	  	  	  
	
    Register of legal entities (district of 
	200 profit shares 	4.9407% 	3.9867% 
	
    Brussels) number 0879.436.147 
	  	  	  
	
    Monsieur Hugues BULTOT 
	  	  	  
	
    Avenue Victor Jacobs, 78, 
	300 	7.4111% 	5.9800% 
	
    1040 Brussels 
	  	  	  
	
    Belgium 
	  	  	  
	
    Monsieur José CASTILLO 
	  	  	  
	
    FERNANDEZ, 
	  	  	  
	
    Rue de la Buanderie, 188/0007 boîte 3.1 
	300 	7.4111% 	5.9800% 
	
    1080 Brussels 
	  	  	  
	
    Belgium 
	  	  	  
	
    4FORCELLS SPRL 
	24 	0,5929% 	0,4784% 

- 44 - 

Execution version 

	 CELL THERAPY HOLDING SA
      SHAREHOLDERS  
	I. Name & address/registered office    	II. CTH Common Stock 	III. % in Priveco before 	IV. % in Priveco after 
	  	(shares and profit shares) 	conversion of the Convertible 	conversion of the Convertible 
	  	  	Bonds 	Bonds 
	  	  	(% of Consideration Shares at 	(% of the total number of 
	  	  	Closing) 	Consideration Shares after 
	  	  	  	conversion of the Convertible 
	  	  	  	Bonds) 
	
    Rue Adrienne Bolland, 8, 
	  	  	  
	
    6041 Gosselies, 
	  	  	  
	
    Belgium 
	400 profit shares 	9,8814% 	7,9734% 
	
    Register of legal entities (district of 
	  	  	  
	
    Charleroi) number 0838.206.142 
	  	  	  
	
    TOTAL 
	  	  	  
	
      
	1,224 shares and 600 profit 	  	  
	
      
	shares 	  	  

- 45 - 

Execution version 

B. Holders of Convertible Bonds

	I. Name, address and registration number 	II. Number of Convertible Bonds 	III. % in Priveco after conversion of 
	  	  	the Convertible Bonds (% of the total 
	  	  	number of Consideration Shares after 
	  	  	conversion of the Convertible Bonds) 
	
    Olivier DAVIGNON 
	500 	6.0238% 
	
    Avenue du Vivier d’Oie, 59 
	  	  
	
    1180 Brussels 
	  	  
	
    Belgium 
	  	  
	
    INVEST4MTCORG 
	100 	1.2048% 
	
    Unlimited partnership 
	  	  
	
    (société civile de droit commun de droit belge) 
	  	  
	
    Avenue des Cormorans 15 
	  	  
	
    1150 Brussels 
	  	  
	
    Belgium 
	  	  
	
    Claude JOTTRAND 
	150 	1.8071% 
	
    Square Larousse 16 
	  	  
	
    1190 Brussels 
	  	  
	
    Belgium 
	  	  
	
    HOLOGRAMME SA 
	100 	1.2048% 
	
    Chemin de la tour de Champel, 6 
	  	  
	
    1206 Geneva 
	  	  
	
    Switzerland 
	  	  
	
     
    
	  	  
	
    Registered with the register of commerce of the canton of 
	  	  
	
    Geneva under number CH-660.3.083.013-9 
	  	  
	
    LIFE SCIENCES RESEARCH PARTNERS VZW 
	250 	3.0119% 
	
    Herestraat 49 bte 913 
	  	  
	
    3000 Leuven 
	  	  
	
    Belgium 
	  	  
	
     
    
	  	  
	
    Register of legal entities (district of Leuven) number 
	  	  
	
    0435.768.243 
	  	  

- 46 - 

Execution version 

	I. Name, address and registration number    	II. Number of Convertible Bonds 	III. % in Priveco after conversion of 
	  	  	the Convertible Bonds (% of the total 
	  	  	number of Consideration Shares after 
	  	  	conversion of the Convertible Bonds) 
	
    Alexandre SCHMITZ 
	100 	1.2048% 
	
    34 Nassim Road 
	  	  
	
    258419 Singapore 
	  	  
	
    THEODORUS SCA 
	100 	1.2048% 
	
    Avenue Joseph Wybran 40 
	  	  
	
    1070 Anderlecht 
	  	  
	
    Belgium 
	  	  
	
      
	  	  
	
    Register of legal entities (district of Brussels)
      number 
	  	  
	
    0859.775.138 
	  	  
	
    THEODORUS III SA 
	300 	3.6143% 
	
    Avenue Joseph Wybran 40 
	  	  
	
    1070 Anderlecht 
	  	  
	
    Belgium 
	  	  
	
      
	  	  
	
    Register of legal entities (district of Brussels)
      number 
	  	  
	
    0535.803.353 
	  	  
	
    TOTAL 
	1,600 convertible bonds 	  

- 47 - 

Execution version 

SCHEDULE 2 

TO THE SHARE EXCHANGE AGREEMENT AMONG ORGENESIS 
INC.,
MASTHERCELL SA, CELL THERAPY HOLDING SA AND THE SELLINGSHAREHOLDERS 
AS

SET OUT IN THE 
SHARE EXCHANGE AGREEMENT 

CERTIFICATE OF NON-U.S. SHAREHOLDER 

OF 

ORGENESIS INC. 

In connection with the issuance of common stock (the
“Consideration Shares”) of Orgenesis Inc. a Nevada corporation (“Pubco”), to the
undersigned, pursuant to that certain Share Exchange Agreement dated November
3rd, 2014 (the “Agreement”), among Pubco, MasTHerCell SA and Cell Therapy
Holding SA, both companies incorporated pursuant to the laws of Belgium
(“Priveco”) and the shareholders of Priveco as set out in the Agreement (each, a
“Selling Shareholder”), the undersigned hereby agrees, acknowledges, represents
and warrants that: 

	1. 	
      the undersigned is not a “U.S. Person” as such term is
      defined by Rule 902 of Regulation S under the United States Securities Act
      of 1933, as amended (“U.S. Securities Act”) (the definition of which
      includes, but is not limited to, an individual resident in the U.S. and an
      estate or trust of which any executor or administrator or trust,
      respectively is a U.S. Person and any partnership or corporation organized
      or incorporated under the laws of the U.S.);

	 	 
	2. 	
      none of the Consideration Shares have been or will be
      registered under the U.S. Securities Act, or under any state securities or
      “blue sky” laws of any state of the United States, and may not be offered
      or sold in the United States or, directly or indirectly, to U.S. Persons,
      as that term is defined in Regulation S, except in accordance with the
      provisions of Regulation S or pursuant to an exemption from, or in a
      transaction not subject to, the registration requirements of the U.S.
      Securities Act and in compliance with any applicable state and foreign
      securities laws;

	 	 
	3. 	
      the undersigned understands and agrees that offers and
      sales of any of the Consideration Shares prior to the expiration of a
      period of one year after the date of original issuance of the
      Consideration Shares (the one year period hereinafter referred to as the
      Distribution Compliance Period) shall only be made in compliance with the
      safe harbor provisions set forth in Regulation S, pursuant to the
      registration provisions of the U.S. Securities Act or an exemption
      therefrom, and that all offers and sales after the Distribution Compliance
      Period shall be made only in compliance with the registration provisions
      of the U.S. Securities Act or an exemption therefrom and in each case only
      in accordance with applicable state and foreign securities laws;

	 	 
	4. 	
      the undersigned understands and agrees not to engage in
      any hedging transactions involving any of the Consideration Shares unless
      such transactions are in compliance with the provisions of the U.S.
      Securities Act and in each case only in accordance with applicable state
      and provincial securities laws;

1 

Execution version 

	5. 	
      the undersigned is acquiring the Consideration Shares for
      investment only and not with a view to resale or distribution and, in
      particular, it has no intention to distribute either directly or
      indirectly any of the Consideration Shares in the United States or to U.S.
      Persons;

	 	 
	6. 	
      the undersigned has not acquired the Consideration Shares
      as a result of, and will not itself engage in, any directed selling
      efforts (as defined in Regulation S under the U.S. Securities Act) in the
      United States in respect of the Consideration Shares which would include
      any activities undertaken for the purpose of, or that could reasonably be
      expected to have the effect of, conditioning the market in the United
      States for the resale of any of the Consideration Shares; provided,
      however, that the undersigned may sell or otherwise dispose of the
      Consideration Shares pursuant to registration thereof under the U.S.
      Securities Act and any applicable state and provincial securities laws or
      under an exemption from such registration requirements;

	 	 
	7. 	
      the statutory and regulatory basis for the exemption
      claimed for the sale of the Consideration Shares, although in technical
      compliance with Regulation S, would not be available if the offering is
      part of a plan or scheme to evade the registration provisions of the U.S.
      Securities Act or any applicable state and provincial securities
    laws;

	 	 
	8. 	
      the undersigned has not undertaken, and will have no
      obligation, to register any of the Consideration Shares under the U.S.
      Securities Act;

	 	 
	9. 	
      Pubco is entitled to rely on the acknowledgements,
      agreements, representations and warranties and the statements and answers
      of the Selling Shareholders contained in the Agreement and those of the
      undersigned contained in this Certificate, and the undersigned will hold
      harmless Pubco from any loss or damage either one may suffer as a result
      of any such acknowledgements, agreements, representations and/or
      warranties made by the Selling Shareholders and/or the undersigned not
      being true and correct in accordance with the provisions of the
      Agreement;

	 	 
	10. 	
      the undersigned has been advised to consult their own
      respective legal, tax and other advisors with respect to the merits and
      risks of an investment in the Consideration Shares and, with respect to
      applicable resale restrictions, is solely responsible (and Pubco is not in
      any way responsible) for compliance with applicable resale
      restrictions;

	 	 
	11. 	
      none of the Consideration Shares are listed on any stock
      exchange or automated dealer quotation system and no representation has
      been made to the undersigned that any of the Consideration Shares will
      become listed on any stock exchange or automated dealer quotation system,
      except that currently certain market makers make market in the common
      shares of Pubco on the OTC Bulletin Board;

	 	 
	12. 	
      the undersigned is outside the United States when
      receiving and executing this Agreement and is acquiring the Consideration
      Shares as principal for their own account, for investment purposes only,
      and not with a view to, or for, resale, distribution or fractionalization
      thereof, in whole or in part, and no other person has a direct or indirect
      beneficial interest in the Consideration Shares;

	 	 
	13. 	
      neither the SEC nor any other securities commission or
      similar regulatory authority has reviewed or passed on the merits of the
      Consideration Shares;

	 	 
	14. 	
      the Consideration Shares are not being acquired, directly
      or indirectly, for the account or benefit of a U.S. Person or a person in
      the United States;

Execution version 

	15. 	
      the undersigned acknowledges and agrees that Pubco shall
      refuse to register any transfer of Consideration Shares not made in
      accordance with the provisions of Regulation S, pursuant to registration
      under the U.S. Securities Act, or pursuant to an available exemption from
      registration under the U.S. Securities Act;

	 	 
	16. 	
      the undersigned understands and agrees that the
      Consideration Shares will bear the following
legend:

	 	
      “THE SECURITIES REPRESENTED HEREBY HAVE BEEN OFFERED IN
      AN OFFSHORE TRANSACTION TO A PERSON WHO IS NOT A U.S. PERSON (AS DEFINED
      HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF
      1933, AS AMENDED (THE “1933 ACT”). 
	 
	 	  	 
	 	
      NONE OF THE SECURITIES REPRESENTED HEREBY HAVE BEEN
      REGISTERED UNDER THE 1933 ACT, OR ANY U.S. STATE SECURITIES LAWS, AND,
      UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY,
      IN THE UNITED STATES (AS DEFINED HEREIN) OR TO U.S. PERSONS EXCEPT IN
      ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT,
      PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 ACT, OR
      PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT
      TO, THE REGISTRATION REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY IN
      ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING
      TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN
      COMPLIANCE WITH THE 1933 ACT. “UNITED STATES” AND “U.S. PERSON” ARE AS
      DEFINED BY REGULATION S UNDER THE 1933 ACT.” 
	 

	17. 	
      the address of the undersigned included herein is the
      sole address of the undersigned as of the date of this
  certificate.

IN WITNESS WHEREOF, I have executed this Certificate of
Non-U.S. Shareholder. 

	Date: ________________________________________________, 2014 	 
	 	 
	Signature 	  
	 	 
	 	 
	Print Name 	  
	 	 
	Title (if applicable) 	  
	 	 
	Address 	  
	 	 

Execution version 

SCHEDULE 2B 
     TO THE
SHARE EXCHANGE AGREEMENT AMONG ORGENESIS INC. 
MASTHERCELL SA, CELL THERAPY
HOLDING SA AND THE SELLING SHAREHOLDERS
AS SET OUT IN THE 
SHARE EXCHANGE
AGREEMENT 

CERTIFICATE OF U.S. SHAREHOLDER 

OF 

ORGENESIS INC. 

In connection with the issuance of common stock ("Pubco Common
Stock") of Orgenesis Inc. a Nevada corporation ("Pubco"), to the undersigned,
pursuant to that certain Share Exchange Agreement dated November 3rd, 2014 among
Pubco, MasTherCell SA and Cell Therapy Holding SA, both companies incorporated
under the laws of Belgium (the "Target") and the Target’s shareholders, the
undersigned hereby agrees, represents and warrants that he, she or it: 

	1. 	Acquired Entirely for Own
      Account. 
	  	  	  
		
      The undersigned represents and warrants that he, she or
      it is acquiring the Pubco Common Stock solely for the undersigned’s own
      account for investment and not with a view to or for sale or distribution
      of the Pubco Common Stock or any portion thereof and without any present
      intention of selling, offering to sell or otherwise disposing of or
      distributing the Pubco Common Stock or any portion thereof in any
      transaction other than a transaction complying with the registration
      requirements of the U.S. Securities Act of 1933, as amended (the
      "Securities Act"), and applicable state and provincial securities laws, or
      pursuant to an exemption therefrom. The undersigned also represents that
      the entire legal and beneficial interest of the Pubco Common Stock that
      he, she or it is acquiring is being acquired for, and will be held for,
      the undersigned’s account only, and neither in whole nor in part for any
      other person or entity. 

	  	  	  
	2. 	Information Concerning Pubco.
    
	  	  	  
		
      The undersigned acknowledges that he, she or it has
      received all such information as the undersigned deems necessary and
      appropriate to enable him, her or it to evaluate the financial risk
      inherent in making an investment in the Pubco Common Stock. The
      undersigned further acknowledges that he, she or it has received
      satisfactory and complete information concerning the business and
      financial condition of Pubco in response to all inquiries in respect
      thereof. 

	  	  	  
	3. 	Economic Risk and Suitability.
    
	  	  	  
	  	The undersigned represents and
      warrants as follows: 
	  	  	  
		(a) 	
      the undersigned realizes that the Pubco Common Stock
      involves a high degree of risk and are a speculative investment, and that
      he, she or it is able, without impairing the undersigned’s financial
      condition, to hold the Pubco Common Stock for an indefinite period of
      time; 

	  	  	
      

		(b) 	
      the undersigned recognizes that there is no assurance of
      future profitable operations and that investment in Pubco involves
      substantial risks, and that the undersigned has taken full cognizance of
      and understands all of the risk factors related to the Pubco Common Stock;
      

1 

Execution version 

	 	(c) 	
      the undersigned has carefully considered and has, to the
      extent the undersigned believes such discussion necessary, discussed with
      the undersigned’s professional legal, tax and financial advisors the
      suitability of an investment in Pubco for the particular tax and financial
      situation of the undersigned and that the undersigned and/or the
      undersigned’s advisors have determined that the Pubco Common Stock is a
      suitable investment for the undersigned;

	 	 	 
	 	(d) 	
      the financial condition and investment of the undersigned
      are such that he, she or it is in a financial position to hold the Pubco
      Common Stock for an indefinite period of time and to bear the economic
      risk of, and withstand a complete loss of, the value of the Pubco Common
      Stock;

	 	 	 
	 	(e) 	
      the undersigned alone, or with the assistance of
      professional advisors, has such knowledge and experience in financial and
      business matters that the undersigned is capable of evaluating the merits
      and risks of acquiring the Pubco Common Stock, or has a pre-existing
      personal or business relationship with Pubco or any of its officers,
      directors, or controlling persons of a duration and nature that enables
      the undersigned to be aware of the character, business acumen and general
      business and financial circumstances of Pubco or such other
  person;

	 	 	 
	 	(f) 	
      if the undersigned is a partnership, trust, corporation
      or other entity: (1) it was not organized for the purpose of acquiring the
      Pubco Common Stock (or all of its equity owners are "accredited investors"
      as defined in Section 6 below); (2) it has the power and authority to
      execute this Certificate and the person executing said document on its
      behalf has the necessary power to do so; (3) its principal place of
      business and principal office are located within the state set forth in
      its address below; and (4) all of its trustees, partners and/or
      shareholders, whichever the case may be, are bona fide residents of said
      state;

	 	 	 
	 	(g) 	
      the undersigned understands that neither Pubco nor any of
      its officers or directors has any obligation to register the Pubco Common
      Stock under any federal or other applicable securities act or
  law;

	 	 	 
	 	(h) 	
      the undersigned has relied solely upon the advice of his
      or her representatives, if any, and independent investigations made by the
      undersigned and/or his or her the undersigned representatives, if any, in
      making the decision to acquire the Pubco Common Stock and acknowledges
      that no representations or agreements other than those set forth in the
      Share Exchange Agreement have been made to the undersigned in respect
      thereto;

	 	 	 
	 	(i) 	
      all information which the undersigned has provided
      concerning the undersigned himself, herself or itself is correct and
      complete as of the date set forth below, and if there should be any
      material change in such information prior to the issuance of the Pubco
      Common Stock, he, she or it will immediately provide such information to
      Pubco;

	 	 	 
	 	(j) 	
      the undersigned confirms that the undersigned has
      received no general solicitation or general advertisement and has attended
      no seminar or meeting (whose attendees have been invited by any general
      solicitation or general advertisement) and has received no advertisement
      in any newspaper, magazine, or similar media, broadcast on television or
      radio regarding acquiring the Pubco Common Stock; and

	 	 	 
	 	(k) 	
      the undersigned is at least 21 years of age and is a
      citizen of the United States residing at the address indicated
    below.

- 3 - 

Execution version 

	4. 	
      Restricted Securities.

The undersigned acknowledges that Pubco
has hereby disclosed to the undersigned in writing: 

	 	(a) 	
      the Pubco Common Stock that the undersigned is acquiring
      have not been registered under the Securities Act or the securities laws
      of any state of the United States, and such securities must be held
      indefinitely unless a transfer of them is subsequently registered under
      the Securities Act or an exemption from such registration is available;
      and

	 	 	 
	 	(b) 	
      Pubco will make a notation in its records of the above
      described restrictions on transfer and of the legend described
    below.

	5. 	Legends. 

The undersigned agrees that Pubco
Common Stock will bear the following legends: 

	 	
      "THESE SHARES OF COMMON STOCK HAVE NOT BEEN REGISTERED
      UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED ("1933 ACT") OR
      THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES AND MAY BE OFFERED,
      SOLD OR OTHERWISE TRANSFERRED ONLY (I) TO THE COMPANY, (II) OUTSIDE THE
      UNITED STATES IN COMPLIANCE WITH RULE 904 OF REGULATION S UNDER THE 1933
      ACT, (III) IN COMPLIANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE
      1933 ACT PROVIDED BY RULE 144 THEREUNDER, OR (IV) IN COMPLIANCE WITH
      ANOTHER EXEMPTION FROM REGISTRATION, IN EACH CASE AFTER PROVIDING EVIDENCE
      SATISFACTORY TO THE COMPANY THAT SUCH TRANSFER MAY BE MADE WITHOUT
      REGISTRATION UNDER THE 1933 ACT. HEDGING TRANSACTIONS INVOLVING THE
      SECURITIES REPRESENTED HEREBY MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE
      WITH THE 1933 ACT." 
	 

	6. 	
      Suitable Investor.

In order to establish the
qualification of the undersigned to acquire the Pubco Common Stock, the
information requested in either subsection 6(a) or (b) below must be supplied.

     (a) The undersigned is an
"accredited investor," as defined in Securities and Exchange Commission (the
"SEC") Rule 501. An "accredited investor" is one who meets any of the
requirements set forth below. The undersigned represents and warrants that the
undersigned falls within the category (or categories) marked. PLEASE INDICATE
EACH CATEGORY OF ACCREDITED INVESTOR THAT YOU, THE UNDERSIGNED, SATISFY, BY
PLACING AN "X" ON THE APPROPRIATE LINE BELOW. 

	_____ Category 1. 	A bank, as defined in Section 3(a)(2) of the
      Securities Act, whether acting in its individual or fiduciary capacity; or
    
	  	  
	_____ Category 2. 	A savings and loan association or other
      institution as defined in Section 3(a) (5) (A) of the Securities Act,
      whether acting in its individual or fiduciary capacity; or 
	  	  
	_____ Category 3. 	A broker or dealer registered pursuant to
      Section 15 of the Securities Exchange Act of 1934; or 
	  	  
	_____ Category 4. 	An insurance company as defined in Section
      2(13) of the Securities Act; or 

- 4 - 

Execution version 

	_____ Category 5. 	
      An investment company registered under the Investment
      Company Act of 1940; or 

	  	
       

	_____ Category 6. 	
      A business development company as defined in Section 2(a)
      (48) of the Investment Company Act of 1940; or 

	  	
       

	_____ Category 7. 	
      A small business investment company licensed by the U.S.
      Small Business Administration under Section 301(c) or (d) of the Small
      Business Investment Act of 1958; or 

	  	
       

	_____ Category 8. 	
      A plan established and maintained by a state, its
      political subdivision or any agency or instrumentality of a state or its
      political subdivisions, for the benefit of its employees, with assets in
      excess of $5,000,000; or 

	  	
       

	_____ Category 9. 	
      An employee benefit plan within the meaning of the
      Employee Retirement Income Security Act of 1974 in which the investment
      decision is made by a plan fiduciary, as defined in Section 3(2 1) of such
      Act, which is either a bank, savings and loan association, insurance
      company or registered investment advisor, or an employee benefit plan with
      total assets in excess of $5,000,000 or, if a self-directed plan, the
      investment decisions are made solely by persons who are accredited
      investors; or 

	  	
       

	_____ Category 10. 	
      A private business development company as defined in
      Section 202(a) (22) or the Investment Advisers Act of 1940; or 

	  	
       

	_____ Category 11. 	
      An organization described in Section 501(c)(3) of the
      Internal Revenue Code, a corporation, a Massachusetts or similar business
      trust, or a partnership, not formed for the specific purpose of acquiring
      the Interest, with total assets in excess of $5,000,000; or 

	  	
       

	_____ Category 12. 	
      A director or executive officer of Pubco; or 

	  	
       

	_____ Category 13. 	
      A natural person whose individual net worth, or joint net
      worth with that person’s spouse, excluding the value and any debt
      registered on their primary residence,exceeds $1,000,000; or 

	  	
       

	_____ Category 14. 	
      A natural person who had an individual income in excess
      of $200,000 in each of the two most recent years or joint income with that
      person’s spouse in excess of $300,000 in each of those years and has a
      reasonable expectation of reaching the same income level in the current
      year; or 

	  	
       

	_____ Category 15. 	
      A trust, with total assets in excess of $5,000,000, not
      formed for the specific purpose of acquiring the Interest, whose purchase
      is directed by a sophisticated person as described in SEC Rule
      506(b)(2)(ii); or 

	  	
       

	_____ Category 16. 	
      An entity in which all of the equity owners are
      accredited investors. 

- 5 - 

Execution version 

	                   (b)
      The undersigned is not an accredited investor and meets the requirements
      set forth below. PLEASE INDICATE THAT YOU, THE UNDERSIGNED, SATISFY THESE
      REQUIREMENTS BY PLACING AN "X" ON THE LINE BELOW. 

	______	
      The undersigned, either alone or with the undersigned’s
      representative, has such knowledge, skill and experience in business,
      financial and investment matters so that the undersigned is capable of
      evaluating the merits and risks of an investment in the Pubco Common
      Stock. To the extent necessary, the undersigned has retained, at the
      undersigned’s own expense, and relied upon, appropriate professional
      advice regarding the investment, tax and legal merits and consequences of
      owning the Pubco Common Stock. In addition, the amount of the
      undersigned’s investment in the Pubco Common Stock does not exceed ten
      percent (10%) of the undersigned’s net worth. The undersigned agrees to
      furnish any additional information requested to assure compliance with
      applicable federal and state securities laws in connection with acquiring
      the Pubco Common Stock. 

	7. 	
      Understandings.

The undersigned understands,
acknowledges and agrees that: 

	 	(a) 	
      no federal or state agency has made any finding or
      determination as to the accuracy or adequacy of the Disclosure Documents
      or as to the fairness of the terms of this offering for investment nor any
      recommendation or endorsement of the Pubco Common Stock;

	 	 	 
	 	(b) 	
      this offering is intended to be exempt from registration
      under the Securities Act by virtue of Section 4(2) of the Securities Act,
      which is in part dependent upon the truth, completeness and accuracy of
      the statements made by the undersigned herein;

	 	 	 
	 	(c) 	
      the Pubco Common Stock are "restricted securities" in the
      U.S. under the Securities Act. There can be no assurance that the
      undersigned will be able to sell or dispose of the Pubco Common Stock. It
      is understood that in order not to jeopardize this offering’s exempt
      status under Section 4(2) of the Act, any transferee may, at a minimum, be
      required to fulfill the investor suitability requirements
    thereunder;

	 	 	 
	 	(d) 	
      the representations, warranties and agreements of the
      undersigned contained herein and in any other writing delivered in
      connection with the transactions contemplated hereby shall be true and
      correct in all respects on and as of the date the Pubco Common Stock is
      acquired as if made on and as of such date; and

	 	 	 
	 	(e) 	
      THE PUBCO COMMON STOCK MAY NOT BE TRANSFERRED, RESOLD OR
      OTHERWISE DISPOSED OF EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND ANY
      OTHER APPLICABLE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION
      THEREFROM. THE UNDERSIGNED SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO
      BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF
      TIME.

- 6 - 

Execution version 

IN WITNESS WHEREOF, I have executed
this Certificate. 

	__________________________________                                                                                                                                                               
    	Date: __________________________________ ,
      2014 
	 	 
	Signature 	  
	 	 
	__________________________________	 
	Print Name 	  
	__________________________________	 
	Title (if applicable) 	  
	__________________________________	 
	Address 	  
	 	 
	__________________________________	 

Execution version 

SCHEDULE 3 

     TO THE SHARE EXCHANGE AGREEMENT
AMONG ORGENESIS
 INC., MASTHERCELL SA, CELL THERAPY HOLDING SA AND THE
SELLING 
SHAREHOLDERS AS 
SET OUT IN THE 
SHARE EXCHANGE AGREEMENT 

DIRECTORS AND OFFICERS OF PRIVECO 

MASTHERCELL SA 

Directors: 

Marie Bouillez 

Hugues Bultot 

José Castillo Fernandez 

Jean-Paul Prieels 

Françoise Magerman 

CELL THERAPY HOLDING SA 

Directors: 

Hugues Bultot 

Olivier Belenger 

Patrick Stragier 

1 

Execution version 

SCHEDULE 4 

TO THE SHARE EXCHANGE AGREEMENT AMONG ORGENESIS 
INC.,
MASTHERCELL SA, CELL THERAPY HOLDING SA AND THE 
SELLINGSHAREHOLDERS AS SET
OUT IN THE 
SHARE EXCHANGE AGREEMENT 

DIRECTORS AND OFFICERS OF PUBCO 

Directors: 

Vered Caplan, Director and CEO 

Guy Yashin, Director 

Yaron Adler, Director 

Etti Hanochi, Director 

David Sidransky, Director 

Officers: 

Neil Reithinger, - CFO 

Jacob BenArie, CEO of Orgenesis
Ltd.

Scott Carmer, CEO of Orgenesis Maryland
Inc. 

Execution version 

SCHEDULE 5 

     TO THE SHARE EXCHANGE AGREEMENT
BETWEEN ORGENESIS INC., 
MASTHERCELL SA, CELL THERAPY HOLDING SA AND THE
SELLINGSHAREHOLDERS AS 
SET OUT IN THE 
SHARE EXCHANGE AGREEMENT 

PRIVECO INTELLECTUAL PROPERTY 

	1. 	
      Trade Marks:

Masthercell owns a trademark, registered under number 11604
with the Benelux Office for Intellectual Property. 

	2. 	
      Know-how

Developing, defending, deploying through the organization and
valuing to the benefit of its customer the know-how and intellectual property
related to its core business, is at the heart of Masthercell's strategy. 

While strictly maintaining know-how and IP rights of its
customer, Masthercell has been able to develop, with the input of its founders
and of its employees, major differentiating specific know-how in : 

	
  Small scale automated production method of T-Cells 

  
	
  New purification methods of viral vectors 

  
	
  Mass production of mesenchymal stem cells 

  
	
  Streamlined process for integrated cell detachment, separation,
  concentration, washing, formulation and filling of mesenchymal stem cells at
  very large scale 

  
	
  New (cryo)preservation methods for stem cells 

  
	
  Specific ingredients of culture media for stem/primary cells. 

With the help of Patent Attorney and IP strategists,
Masthercell will choose the most efficient protection strategy to maximize the
value creation for its customers and its shareholders through patent
applications, through design and development of specific equipments and/or
methods, ...or simply by know-how and trade secrets. 

In order to facilitate: 

	- 	Its customer base expansion; 
	 	 
	- 	Its international expansion;

Masthercell has developed a very innovative modular quality
system which allows fast-track deployment for any specific therapy or any
specific regional or national quality system requirement.

Execution version 

SCHEDULE 6 

     TO THE SHARE EXCHANGE AGREEMENT
BETWEEN ORGENESIS INC., 
MASTHERCELL SA, CELL THERAPY HOLDING SA AND THE
SELLINGSHAREHOLDERS AS 
SET OUT IN THE 
SHARE EXCHANGE AGREEMENT 

PRIVECO MATERIAL CONTRACTS 

	1. 	
      CORPORATE
CONTRACTS

	• 	Issuance of a convertible bonds' loan and
      extract published in Belgian Official Journal - 13 November 2013 
	 	 
	• 	Deed of incorporation of MaSTherCell SA - 4
      November 2011 
	 	 
	• 	Deed of incorporation of Cell Therapy Holding
      SA - 25 October 2011 
	 	 
	• 	Subscription and shareholders agreement - 18
      September 2014 
	 	 
	• 	Certificate of formation for-profit corporation
      of WalTex Cells Inc - Form 201 

	2. 	
      OTHER CONTRACTS

	• 	
      Contract between The Research Valley Partnership Inc and
      MaSTherCell SA (consulting and advisory services) - 12 November 2013
    

	  	
       

	• 	
      Construction Contract between MaSTherCell SA, Axis Europ,
      SC Laborator Project SRL and SERAM - 16 March 2012 (in 2 parts : even
      & odd pages) 

	  	
       

	• 	
      Laboratory Lease Agreement "Biopark Incubator 2" between
      IGRETEC and MaSTherCell SA - 29 March 2012 

	  	
       

	• 	
      Lease Agreement "Biopark Incubator" between IGRETEC and
      MaSTherCell SA - 12 November 2012 

	  	
       

	• 	
      Evaluation agreement Quantum TM Cell Expansion System®
      between Terumo BCT Europe NV and MaSTherCell - 2 July 2014 

	  	
       

	• 	
      Service agreement between Regenesys BVBA and MaSTherCell
      SA - 14 July 2014 

	  	
       

	• 	
      Service agreement between Bellicum and MaSTherCell SA - 6
      February 2014 

	  	
       

	• 	
      Letter of Intent re: Technology Transfer & Execution
      of Phase III Manufacturing Activities for Clinical Trials in Europe
      between Cardio3 Biosciences and MaSTherCell SA - 8 August 2014 

	  	
       

	• 	
      Letter of Intent re Technology Transfer & Execution
      of Phase I/II Manufacturing Activities for Clinical Trials in Europe
      between Bellicum Pharmaceuticals and MaSTherCell SA - 13 November 2013
    

Execution version 

	• 	Service agreement between Orgenesis SPRL and
      MaSTherCell SA - 23 June 2014 
	 	 
	• 	Service agreement between ImCyse and
      MaSTherCell SA - 19 March 2013 
	 	 
	• 	Cooperation agreement between Deloitte and
      MaSTherCell SA - 28 June 2014 
	 	 
	• 	Management and consulting agreement between CTJ
      Consulting and MaSTherCell SA - 10 September 2014 
	 	 
	• 	Share transfer agreement between Cell Therapy
      Holding SA and Mr Eric Mathieu - 28 July 2014 
	 	 
	• 	Share transfer agreement between Cell Therapy
      Holding SA and Mr Guillaume De Viron - 28 July 2014 
	 	 
	• 	Share transfer agreement between Cell Therapy
      Holding SA and Mr Hugues Bultot - 28 July 2014 
	 	 
	• 	Share transfer agreement between Cell Therapy
      Holding SA and Mr José Antonio Castillo Fernandez - 28 July 2014 
	 	 
	• 	Share transfer agreement between Cell Therapy
      Holding SA and JPP Consulting SPRL - 24 July 2014 
	 	 
	• 	Assignment of claim between Cell Therapy
      Holding SA and JPP Consulting SPRL - 1 August 2014 
	 	 
	• 	Management and consulting agreement between
      ECOM Bioprocess SCS and MaSTherCell SA - 31 January 2014 
	 	 
	• 	Consulting agreement between Axolotl
      Biosciences SPRL and MaSTherCell SA - 8 March 2013 
	 	 
	• 	Agreement between Auxiliastra SPRL and
      MaSTherCell SA 
	 	 
	• 	Letter Sambrinvest to MaSTherCell SA regarding
      loan (250K EUR) - 13 March 2014 
	 	 
	• 	Grant of credit line (800K EUR) between ING and
      MaSTherCell SA - February 2014 
	 	 
	• 	Grant of investment credit (1.4 million EUR) -
      August 2012 
	 	 
	• 	Grant of a subordinated loan between Fonds de
      capital à Risque - Convergence SA and MaSTherCell SA (250K EUR) - 6 August
      2012 
	 	 
	• 	Loan Agreement between the Walloon Region and
      MaSTherCell SA (1 million EUR) - 20 August 2012 

Execution version 

SCHEDULE 7 

[intentionally left blank] 

 

 

 

Execution version 

SCHEDULE 8 

[intentionally left blank]

 

 

 

 

Execution version 

SCHEDULE 9 

TO THE SHARE EXCHANGE AGREEMENT BETWEEN ORGENESIS INC.,

MASTHERCELL SA, CELL THERAPY HOLDING SA AND THE SELLING SHAREHOLDERS AS

SET OUT IN THE 
SHARE EXCHANGE AGREEMENT 

ESCROW AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]